Andrew E. Hendifar, MD, MPH PROFESSIONAL CONTACT …

Andrew E. Hendifar, MD, MPH

Curriculum Vitae

December 12, 2018

PROFESSIONAL CONTACT INFORMATION

8700 Beverly Blvd.

Los Angeles, CA 90048

Office: (310) 423-2217

Fax: (310) 967-8486

E-mail: [email protected]

EDUCATION

1996 – 1998 Student Research Fellow, National Institutes of Health

Primary Investigator: Robert Blumenthal, PhD

Influenza hemaglutinin mediated membrane fusion

Membrane Structure and Function, National Cancer Institute

May 1998 University of Maryland

College Park, MD

Degrees: BA-Philosophy; BS-Biochemistry

University of Maryland Honors Program Citation

May 2003 Tulane University School of Medicine

New Orleans, Louisiana

Doctor of Medicine

Master of Public Health, Health Systems Management

2003 – 2006 Resident, Department of Internal Medicine

University of Southern California

Los Angeles, California

2006 – 2007 Chief Resident, Internal Medicine



2007 – 2010 Fellow (Chief), Hematology and Oncology



Andrew E. Hendifar, MD 2

LICENSURE

NPI# 1649473414

License # A88863, California

DEA# BH9107524

BOARD CERTIFICATION

08/15/06 Internal Medicine

11/09/10 Hematology

11/16/11 Medical Oncology

PROFESSIONAL EXPERIENCE

2016 – present Medical Director, Pancreatic Cancer

Samuel Oschin Comprehensive Cancer Center

2012 – present Assistant Professor of Medicine

Medical Oncology Lead, Gastrointestinal Malignancies

David Geffen School of Medicine

Cedars Sinai Medical Center


2003 Health Systems Management Externship

Supervisor: Dwayne Thomas, MD, Chief Executive Officer

Attended JCAHO surveys, and developed an employee retention

program while shadowing the CEO of the Medical Center of New

Orleans, LA.

2010 – 2012 Primary Investigator, Sarcoma, Pancreatic and Phase 1 Studies

Sarcoma Oncology Center

Santa Monica, California


PROFESSIONAL ACTIVITIES

Committee Services

CSMC Committee Services

2014 – 2016 Member, Internal Review Board Committee

2014 – 2017 Member, Pharmacy and Therapeutics Committee

2014 – present Member, Cancer Committee

2014 – present Member, Gastrointestinal Cancer Committee, Southwest Oncology

Group (SWOG) Cancer Research Network

2014 – present Member, PAR-14-242 Microflora & Gastrointestinal (GI) Cancer

Committee

2016 – present Member, End of Life Committee

Other Committee Services

2005 – 2007 Vice President, Joint Committee of Interns and Residents

Service Employees International Union (SEIU) Healthcare

2016 – present Member, Diabetes Mellitus Chronic Pancreatitis Pancreatic Ductal

Adenocarcinoma (DM CP PDAC) Working Group, Consortium for

the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

(CPDPC)

2016 – present Supportive Care Medicine Chair, Precision Promise Consortium,

Pancreatic Cancer Action Network

2018 – present Steering Committee Member, Precision PromiseSM Clinical Trial

Consortium

2018 – present Member, Neuroendocrine Tumors Task Force (NET TF) of the

National Cancer Institute (NCI) Gastrointestinal Steering

Committee

2019 Scientific Advisory Committee (SAC) for MK7339-002: A Phase 2

Study of Olaparib Monotherapy in Participants with Previously

Treated, Homologous Recombination Repair Mutation (HRRm) or

Homologous Recombination Deficiency (HRD) Positive Advanced

Cancer


Professional Associations/Society Memberships

2003 – present Member, American Society of Clinical Oncology

2015 – present Member, North American Neuroendocrine Tumor Society

(NANETS)

Editorial Services

2016 – present Editorial Board, Journal of Gastroenterology, Liver & Pancreatic

Diseases

2018 – present Editorial Board, Journal of Pancreatology

Consulting Activities

None

Community Services

April 2003 Volunteer, “Bridges to Communities.” Extended medical care to

rural Communities in Nicaragua.

2004 – 2007 Volunteer Physician, “Flying Sams.” An organization devoted to

extending medical services to migrant workers in Mexico.

2007 – 2008 Volunteer, ACP Leadership Conference

CSMC Conferences

2015 – 2016 Course Director: Los Angeles Carcinoid Neuroendocrine Tumor

Society & Caring for Carcinoid Foundation (LACNETS & CFCF)

Annual Los Angeles Neuroendocrine Tumor Patient Education

Conference

2016 Course Director, Pancreatic Cancer Conference

2018 Course Director, Gastrointestinal Cancer Conference

2018 Course Director, North American Neuroendocrine Tumor Society

(NANETS) Regional NET Education: The Multidisciplinary

Management of NET Cancers Conference


Workshops

2013 UCLA CTSI Clinical and Translational Research Workshop

2014 UCLA CTSI K Award Workshop

Other CSMC Professional Activities

2012 – present Member, Multi-Disciplinary Pancreatic Cancer Team

2013 – 2014 CS-Link: ICD-10 Physician Champion

2013 – present Member, Pancreatic Cancer Research Team

2014 – present Lead, Gastrointestinal Oncology Algorithm Development

2014 – present Member, Multi-Disciplinary Neuroendocrine Team

2016 – present Medical Director, Pancreatic Cancer

2016 – present Lead, Gastrointestinal Disease Research Group

2019 Member, Center for Integrated Research on Cancer and Lifestyle

(CIRCL)

Other Professional Activities

2001 – 2003 Coordinator, Tulane-Louisiana State University (LSU) Choking

Prevention Program

Led organization involved with training service industry employees

choking rescue and basic life support. Trained over 600 employees

from establishments throughout the city.

2010 – 2012 Sarcoma Oncology Support Group Facilitator

HONORS AND SPECIAL AWARDS

1993 – 1998 Dean’s List, University of Maryland

1998 University of Maryland Honors Citation

1999 Aron’s MD/MPH Scholars Award: A scholarship awarded for

Master of Public Health


2001 Nominee, Secretary’s Award for Innovations in Health

U.S. Department of Health and Human Services

2003 American Federation for Medical Research Student Recognition

Award

2005 First prize; American College of Physicians regional associate

abstract competition

2006 Brautbauer Teaching Award

2010 Top Doctors

2013 – present Super Doctors

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED

Active/Ongoing

09/01/2015 – 08/31/2020 National Institute of Health, 1U01DK108314: Pathophysiology,

Epidemiology, and Prevention of Pancreatogenic Diabetes

Annual funding cost: $252,287

Role: Other significant contributor - consultant as needed, 0% effort

PIs: Stephen Pandol, MD and Mark Goodarzi, MD, PhD

01/01/2018 – 12/31/2018 Cedars-Sinai Precision Health: A Modified “Universal” Testing

Algorithm to Improve the Delivery of Genetic Care to Patients and

Families with Hereditary “High-Risk” Cancer Conditions

Total Cost: $150,000, 5% effort

PIs: Andrew Hendifar, MD and Megan P. Hitchins, PhD

08/01/2018 – 07/31/2021 Department of Defense Peer Reviewed Cancer Research Program

Translational Team Science Award, DoD CA170974: Sensitization

of Therapeutic-Resistant Pancreatic Cancer by Cancer Cell-Specific

Drug Delivery

Annual direct costs: $233,383

Role: Consultant as needed, 0% effort

PIs: Leland Chung, PhD, Stephen Pandol, MD and James

Tomlinson, MD, PhD


Inactive/Completed

None

Pending Grants

04/01/2019 – 03/31/2020 National Institute of Health, R21: A Prospective, Single Center,

Double Blind, Randomized, Crossover Feasibility Study of Oral

Ketamine versus Placebo for the Treatment of Anxiety in Patients

with Pancreatic Cancer

Direct costs/yr.: $150,000

Role: Co-investigator, 5% effort

PI: Scott Irwin, MD, PhD

RESEARCH FOCUS AND INTERESTS

Clinical Trials*

* Annual funding cost and % effort are unavailable for these clinical trials due to the nature of

funding and data availability. Costs are generated per patient activity. Number of patients

enrolled is provided as a proxy for effort on each trial. Information is provided as available.

02/2013 – 10/2019 Advanced Accelerator Applications, AAA-III-01: Multicenter,

Stratified, Open, Randomized, Comparator-controlled, Parallel

Group Phase III Comparing 177Lu-DOTA0-Tyr3-Octreotate to

Octreotide LAR in Inoperable, Progressive, Somatostatin Receptor

Positive, Midgut Carcinoid Tumors.

Primary investigator, no. of patients=18

08/2013 – 06/2023 Novartis Pharmaceuticals, SOM230B2412: An Open-label,

Multi-center Pasireotide Roll-over Protocol for Patients Who Have

Completed a Previous Novartis Sponsored Pasireotide Study and

are Judged by the Investigator to Benefit from Continued

Pasireotide Treatment.


02/2014 – 01/2019 XBiotech, 2012-PT023: A Pivotal Phase III, Monotherapy Study to

Evaluate Survival Using MABp1 as a Monotherapy in Metastatic

Colorectal Cancer Patients with Cachexia.



03/2014 – present SWOG (Southwest Oncology Group), unfunded: Randomized,

Phase II Trial of Pazopanib vs Placebo in Patients with Progressive

Carcinoid Tumors.


04/2015 – 04/2019 Cedars Sinai Medical Center (UCLA CTSI),

IIT2014-03-Hendifar-PanCax: Enteral Feeding for Pancreatic

Cancer Cachexia - A Longitudinal, Single Institution Study of

Enteral Feeding in Advanced Pancreatic Cancer Patients (Treatment

and Underlying Mechanisms of Pancreatic Cancer Cachexia).


05/2015 – 05/2019 Halozyme, Inc., 50-PDA, 150 LUNG: Hyaluronan as a Predictive

and Prognostic Marker for Pancreatic Ductal Adenocarcinoma and

Lung Cancer. Primary investigator.

11/2015 – 01/2024 Alliance (Cooperative Group Study), EA2142: Randomized Phase

II Study of Cisplatin and Etoposide versus Temozolomide and

Capecitabine in Patients with Advanced G3 Non-Small Cell

Gastroenteropancreatic Neuroendocrine Carcinomas. Primary

investigator.

12/2015 – 12/2018 Novartis Pharmaceuticals, SOM230: A Proof of Concept and

Open-label Study to Test the Efficacy and Safety of Pasireotide in

Patients with Ecotopic ACTH-producing Tumors. Co-investigator.

PI: Alain Mita, MD.

03/2016 – 03/2019 Gilead Sciences, GS-US-370-1369: A Phase 1b Study Evaluating

Momelotinib Combined with Capecitabine and Oxaliplatin in

Subjects with Relapsed/Refractory Metastatic Pancreatic Ductal

Adenocarcinoma.


04/2016 – 04/2019 Pharmacyclics, PCYC-1137: A Randomized, Multicenter,

Double-blind, Placebo-controlled, Phase 2/3 Study of the Brutons

Tyrosine Kinase Inhibitor Ibrutinib in Combination with

Nab-paclitaxel and Gemcitabine Versus Placebo in Combination

with Nab-paclitaxel and Gemcitabine, in the First Line Treatment of

Patients with Metastatic Pancreatic Adenocarcinoma.


06/2016 – 06/2019 Merck, MK-3475-158-00: A Clinical Trial of Pembrolizumab

(MK-3475) Evaluating Predictive Biomarkers in Subjects with

Advanced Solid Tumors (KEYNOTE 158).



10/2016 – 10/2019 Halozyme, Inc., HALO-109-301: A Phase 3, Randomized,

Double-Blind, Placebo-Controlled, Multicenter of PEGylated

Recombinant Human Hyaluronidase (PEGPH20) in Combination

with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus

nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High

Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.


02/2017 – 08/2019 Alliance (Cooperative Group Study), EA2161: A Phase II Study of

MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic

Neuroendocrine Tumors (PNET).


02/2017 – 02/2020 AstraZeneca, IIT-2016-01-Tuli-DURVARAD: A Phase 1/II Study

of Durvalumab and Stereotactive Ablative Body Radiotherapy in

Borderline Resectable and Locally Advanced Pancreatic

Adenocarcinoma.

Co-investigator, no. of patients=9. PI: Richard Tuli, MD, PhD.

05/2017 – 05/2020 Stemcentrx, Inc., SCRX001-006: An Open-Label Study of

Rovalpituzumab Tesirine in Subjects with Delta-Like Protein

3-Expressing Advanced Solid Tumors.


06/2017 – 06/2020 Ipsen Pharmaceuticals, IIT2016-07-Hendlfar-OnFX: Phase I Study

of Onivyde (MM-398) and 5-Fluorouracil/Folinic Acid in

Combination with XilonixTM for Advanced Pancreatic Cancer

Patients with Cachexia (ONFX).


10/2017 – 03/2020 AstraZeneca, D419CC00002: A Randomized, Open-label,

Multi-center Phase III Study of Durvalumab and Tremelimumab as

First-line Treatment in Patients with Unresectable Hepatocellular

Carcinoma (HIMALAYA). Primary investigator.

03/2018 – 03/2021 Xencor, Inc., XmAb18087-01: A Phase 1 Multiple Dose Study to

Evaluate the Safety and Tolerability of XmAb®18087 in Subjects

with Advanced Neuroendocrine and Gastrointestinal Stromal

Tumors. Primary investigator.

06/2018 – 07/2020 RGX-202-001: A Phase 1 Study of RGX-202-01, a Small Molecule

Inhibitor of the Creatine Transporter SLC6a8, with or Without

FOLFIRI, in Patients with Advanced Gastrointestinal Malignancies

with Select Expansion Cohorts. Primary investigator.


Other Studies

08/2014 – present Cedars-Sinai Medical Center, unfunded: Treatment Outcomes in

Cholangiocarcinoma Patients. Primary investigator.

10/2014 – present Cedars-Sinai Medical Center, unfunded: Ethnicity and Cancer: A

Single Institution Analysis of Correlation Between Ethnicity and

Cancer. Primary investigator.

07/2015 – present Protocol No. 00039754: Assessment of Hyaluronan expression in

malignancy. Primary investigator.

06/2016 – present Protocol No. 00043427: Neuroendocrine Tumor. Primary

investigator.

01/2017 – present Protocol No. 00044138: Cardiac Complications in Carcinoids.

Primary investigator.

01/2017 – present Protocol No. 00042130: Malignant Pancreatic Neuroendocrine

Tumor Causing Low Blood Glucose Levels. Co-investigator.

03/2017 – present Protocol No. 00049091: PancPROMIS. Primary investigator.

Completed Clinical Trials*

02/2010 – 12/2015 Ipsen Pharmaceuticals, 2-55-52030-729: Extension Study of

Lanreotide Autogel in Entero-Pancreatic Endocrine Tumours.


05/2010 – 06/2015 Novartis Pharmaceuticals, CSOM230D2203: An Open-label,

Multicenter, Single-arm Study of Pasireotide LAR in Patients with

Rare Tumors of Neuroendocrine Origin. Primary investigator.

10/2010 – 08/2016 National Cancer Institute, S0518: Phase III Prospective

Randomized Comparison of Depot Octreotide plus Interferon Alpha

Versus Depot Octreotide plus Bevacizumab (NSC #704865) in

Advanced, Poor Prognosis Carcinoid Patients.


05/2012 – 03/2015 National Cancer Institute, CALGB 80701: Randomized Phase II

Study of Everolimus Alone Versus Everolimus plus Bevacizumab

in Advanced or Metastatic Pancreatic Neuroendocrine Tumors.



07/2012 – 03/2018 Novartis Pharmaceuticals, CBEZ235Z2401: Randomized Phase II

Study of BEZ235 or Everolimus in Advanced Pancreatic

Neuroendocrine Tumors. Primary investigator.

01/2013 – 09/2014 IIT_PancreasMRI: Improving Pancreas Radiotherapy Plans Using

Respiration-driven Anatomic Deformation: A Pilot Study.

Co-investigator, no. of patients=15. PI: Wensha Yang, PhD.

06/2013 – 12/2016 SWOG (Southwest Oncology Group), S1115: Randomized Phase 2,

AZD6244 Hydrogen Sulfate and MK-2206 vs mFOLFOX in

Metastatic Pancreatic Cancer.


06/2013 – 09/2018 Halozyme Therapeutics, Inc., HALO-109-202: A Phase II,

Randomized, Study of PEGPH20 with Nab-paclitaxel plus

Gemcitabine Compared with Nab-paclitaxel plus Gemcitabine,

Stage IV Previously Untreated Pancreatic Cancer.


07/2013 – 03/2017 Phase One Foundation, ITT2012-06-Tuli-Velgemrad: A Phase I

Study of Veliparib (ABT-888) in Combination with Gemcitabine

and Intensity Modulated Radiation Therapy in Patients with Locally

Advanced, Unresectable Pancreatic Cancer.

Co-investigator, no. of patients=34. PI: Richard Tuli, MD, PhD.

01/2014 – 12/2016 Eastern Cooperative Oncology Group, ECOG2211: Randomized,

Phase II, Study of Temozolomide or Temozolomide and

Capecitabine, Patients with Advanced Pancreatic Neuroendocrine

Tumors.


05/2014 – 05/2017 Clovis Oncology, Inc., CO-338-023: Phase 2, Open-Label, Study of

Rucaparib for Patients with Pancreatic Cancer and BRCA Mutation.


06/2014 – 07/2018 Gilead Sciences, GS-US-370-1296: A Phase 2, Randomized,

Double-blind Study of Gemcitabine and Nab-paclitaxel Combined

with Momelotinib in Subjects with Previously Untreated Metastatic

Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding,

Lead-in Phase.



06/2014 – 07/2018 Gilead Sciences, GS-US-370-1296: A Phase 3, Randomized,

Double-blind Placebo-Controlled Study of Gemcitabine and

Nab-paclitaxel + Momelotinib in Subjects with Previously

Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded

by a Dose-finding, Lead-in Phase.

Primary investigator, no. of patients=8 (See previous Phase 2 study

above.)

07/2014 – 06/2016 UCLA CTSI grant number UL1TR000124, CTSI Seed Grant,

funded: Treatment and Underlying Mechanisms of Pancreatic

Cancer Cachexia. Primary Investigator.

01/2015 – 01/2017 Southwest Oncology Group, S1310: Randomized Phase II Trial of

Single Agent Mek Inhibitor Trametnib (GSK1120212) vs.

5-Fluorouracil or Capecitabine in Refractory Advanced Biliary

Cancer. Primary investigator.

02/2015 – 01/2017 Merck and Co., Inc., LKR141071: Quantitating the Expression of

PD-L1 in Resected Gastric and Gastroesophageal Adenocarcinoma.

Co-investigator. PI: Richard Tuli, MD, PhD.

05/2015 – 04/2016 Immunomedics, Inc., IMMU-107-04: An International,

Multi-Center, Double-Blind, Randomized, Phase III Trial of

90Y-Clivatuzumab Tetraxetan plus Low-dose Gemcitabine Versus

Placebo plus Low-Dose Gemcitabine in Patients with Metastatic

(Stage IV) Pancreatic Adenocarcinoma who Received at Least Two

Prior Treatments (PANCRIT-1). Primary investigator.

01/2016 – 08/2017 Cedars-Sinai Medical Center, IIT2015-10-Shinde-Biosens: The

Biosensor Study: Exploratory Study Evaluating the Use of

Wearable Biosensors and Patient Reported Outcomes (PROs) to

Assess Performance Status and Distress in Patients with Cancer.

Co-investigator. PI: Arvind Shinde, MD.

Research Roles

2016 – present Primary Investigator, Precision PromiseSM Clinical Trial

Consortium Site



2012 – present Primary Investigator, Gastrointestinal Oncology Lead




1996 – 1998 Student Research Fellow, National Institutes of Health

Primary Investigator: Robert Blumenthal, PhD

Influenza hemaglutinin mediated membrane fusion

Membrane Structure and Function, National Cancer Institute

1999 – 2001 Clinical Investigator; Primary Investigator: Laura Dunbar MD, PhD

Hyponatremia in community acquired pneumonia

Emergency Medicine Department, Louisiana State University

2002 – 2003 Clinical Investigator; Primary investigator: Karen Desalvo MD,

MPH

Exposure to violence and its health consequences

Department of Medicine, Tulane University School of Medicine

2004 – 2010 Clinical Investigator; Primary Investigator: Heinz-Josef Lenz, MD

The role of hormone pathways in GI carcinogenesis

Prognostic markers for response and survival in stage 2 and 3 colon

cancer

Division of Oncology, University of Southern California

2010 – 2012 Primary Investigator

Focus on drug development and sarcoma research

Sarcoma Oncology Center

INVITED LECTURES AND PRESENTATIONS

1. Hendifar, Jubelin, Dunbar. Hyponatremia in community acquired pneumonia (CAP): Is it

truly marker for Legionella? 1999 American College of Emergency Physicians Research

Forum. Las Vegas, NV. October 11, 1999.

2. Hendifar, Fisher, DeSalvo. Health Correlates of Exposure to Violence. Society of General

Internal Medicine, 2003 Annual Regional Meeting. New Orleans LA.

3. Hendifar, Andrew. Clinical Trials for Soft Tissue Sarcomas. Cedars-Sinai Medical Oncology

Tumor Board. Los Angeles, CA. March 2, 2010.

4. Hendifar, Andrew. Overview of Sarcoma Oncology. Department of Orthopedics Grand

Rounds. University of Southern California. Los Angeles, CA. June 11, 2010.

5. Hendifar, Andrew. Novel Therapies for Sarcomas. 12th Annual Thoracic Oncology

Conference. University of California. San Francisco, CA. November 20, 2010.

6. Hendifar, Andrew. Updates on Pancreatic Cancer. Cedars-Sinai Medical Oncology Tumor

Board. Los Angeles, CA. December 10, 2010.


7. Hendifar, Andrew. Sarcoma. Lunch and Learn. Cancer Wellness Community. Los Angeles,

CA. February 11, 2011.

8. Hendifar, Andrew. Targeting Mesothelioma: Veglin and Angiogenesis Inhibitors. 1st

International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma.

Santa Monica, CA. May 21, 2011.

9. Hendifar, Andrew. Sarcoma Oncology 2011: Updates and Treatment Advances. Division of

Oncology, University of Southern California. Los Angeles, CA. June 10 2011.

10. Hendifar, Andrew. Sarcoma Landscape Overview. Ziopharm Investigators Meeting. New

York, NY. July 23, 2011.

11. Hendifar, Andrew. Recent Advances in Hematology and Oncology. Brotman Medical Center.

Culver City, CA. October 6, 2011.

12. Hendifar, Andrew. Pancreatic Cancer and Il-6 Signaling. Hematology and Oncology Grand

Rounds. Cedars-Sinai Medical Center. Los Angeles, CA. 2012.

13. Hendifar, Andrew. Pancreatic Cancer 2012. Grand Rounds. Cedars-Sinai Medical Center.

Los Angeles, CA. February 22, 2012.

14. Hendifar, Andrew. Challenges in Gastrointestinal Malignancies. Resident Lecture Series.

Cedars-Sinai Medical Center. Los Angeles, CA. January 16, 2013.

15. Hendifar, Andrew. Pancreas Cancer. Educational Lecture: Inpatient Specialty Program.

Cedars-Sinai Medical Center. Los Angeles, CA. April 2, 2013.

16. Andrew Hendifar, Richard Tuli, Nick Nissen. New Therapies and Advances in the Treatment

of Pancreatic Cancer. Cancer Support Community. Los Angeles, CA. July 16, 2013.

17. Hendifar, Andrew. Advances in Pancreatic Cancer. Cedars-Sinai Department of Medicine,

Grand Rounds. Los Angeles, CA. January 10, 2014.

18. Hendifar, Andrew. Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, CA. January

22, 2014.

19. Hendifar, Andrew. New Approaches to Pancreatic Cancer. 21st International Symposium on

Pancreatic & Biliary Endoscopy. Cedars-Sinai Medical Center. Los Angeles, CA. January 31 -

February 2, 2014.

20. Hendifar, Andrew. Advances in Pancreatic Cancer. Brotman Medical Center. Culver City,

CA. April 21, 2014.


21. Hendifar, Andrew. Advances in Pancreatic Cancer. Medicine Grand Rounds. Centinela

Freeman Hospital. Inglewood, CA. April 28, 2014.

22. Hendifar, Andrew. The New Face of Pancreatic Cancer. Advances in Care for the New

Millennium: 20th Anniversary BRCA Gene Symposium. Cedars-Sinai Medical Center. Los

Angeles, CA. September 13, 2014.

23. Hendifar, Andrew. Pancreatic Cancer 2014. Inpatient Hospitalist Lecture Series.

Cedars-Sinai Medical Center. Los Angeles, CA. September 23, 2014.

24. Hendifar, Andrew. Oncologic Emergencies. 3rd Year Inpatient Internal Medicine Student

Case-Based Didactic Session. Cedars-Sinai Medical Center. Los Angeles, CA. February 25,

2015.

25. Hendifar, Andrew. Carcinoid and Neuroendocrine Tumor Clinical Trials. Coronado Island

Library. Coronado, CA. March, 23, 2015.

26. Hendifar, Andrew. Managing Weight Loss in Cancer Patients. Henry Mayo Newhall

Hospital. Valencia, CA. March 26, 2015.

27. Hendifar, Andrew. Pancreatic Cancer 2015: New Breakthroughs on the Horizon. Valley

Presbyterian Hospital. Van Nuys, CA. April 06, 2015.

28. Hendifar, Andrew. Somatostatin Analog Therapy for the Treatment of Neuroendocrine

Tumors. Los Angeles Carcinoid and Neuroendocrine Tumor Support Group. Cedars-Sinai

Medical Center. Los Angeles, CA. May 12, 2015.

29. Hendifar, Andrew. Clinical Trials for Neuroendocrine Tumors. Los Angeles Carcinoid

Neuroendocrine Tumor Society & Caring for Carcinoid Foundation Annual Neuroendocrine

Tumor Patient & Caregiver Educational Conference. Cedars-Sinai Medical Center. Los

Angeles, CA. June 27, 2015.

30. Hendifar A, Hingorani S. High progression free survival and response rate in previously

untreated pancreatic cancer patients with high hyaluronan expression. 2015 European Society

of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer. Barcelona, Spain.

July1, 2015.

31. Hendifar, Andrew. Cancer Cachexia. Hematology and Oncology Grand Rounds.

Cedars-Sinai Medical Center. Los Angeles, CA. October 13, 2015.

32. Hendifar, Andrew. Gastrointestinal Oncology: Cecal Cancer and TB/Pancreatic Cancer.

Samuel Oschin Comprehensive Cancer Institute (SOCCI) Multi-Disciplinary Tumor Board.

Cedars-Sinai Medical Center. Los Angeles, CA. October, 28, 2015.


33. Hendifar, Andrew. Gastric Cancer. GI Fellows Lecture. Cedars-Sinai Medical Center. Los

Angeles, CA. December 1, 2015.

34. Hendifar, Andrew. Gastrointestinal Oncology: Pancreatic Cancers. Samuel Oschin

Comprehensive Cancer Institute (SOCCI) Multi-Disciplinary Tumor Board. Cedars-Sinai

Medical Center. Los Angeles, CA. January 6, 2016.

35. Hendifar, Andrew. Standard and Novel Chemotherapy for Pancreatic Cancer. 23rd

International Symposium on Pancreatic and Biliary Endoscopy. Cedars-Sinai Medical Center.

Los Angeles, CA. January 28, 2016.

36. Hendifar, Andrew. Advances in Pancreatic Cancer Therapy. Cancer Journal Club. Charles R.

Drew University of Medicine & Science. Los Angeles, CA. February 8, 2016.

37. Hendifar, Andrew. Results from the Netter-1 Study. Los Angeles Carcinoid Neuroendocrine

Tumor Society. Cedars-Sinai Medical Center. Los Angeles, CA. February 9, 2016.

38. Hendifar, Andrew. Pancreatic Cancer 2016. Educational Lecture: Inpatient Specialty

Program. Cedars-Sinai Medical Center. Los Angeles, CA. May 3, 2016.

39. Hendifar, Andrew. 1) Medical Oncology Advances for NETs and 2) PRRT: NETTER-1

Results 2016 & Beyond. 2016 Annual Los Angeles Neuroendocrine Tumor Patient Education

Conference. Cedars-Sinai Medical Center. Los Angeles, CA. June 25, 2016.

40. Hendifar, Andrew. Gastrointestinal Oncology: Metastatic Adenocarcinoma, Metastatic

Cancer and Pancreatic Cancer. Samuel Oschin Comprehensive Cancer Institute (SOCCI)

Multi-Disciplinary Tumor Board. Cedars-Sinai Medical Center. Los Angeles, CA. August 17,

2016.

41. Hendifar, Andrew. Lymphoma/Leukemia. 3rd Year Inpatient Internal Medicine Student

Case-Based Didactic Session. Cedars-Sinai Medical Center. Los Angeles, CA. September 7,

2016.

42. Hendifar, Andrew. The Road to Personalized Medicine: Featuring the Fenmore Lectureship

and The Redlich Lectureship: BRCA Mutated Pancreatic Cancer: A New Approach. 5th

Annual New Therapeutics in Oncology. Cedars-Sinai Medical Center. Los Angeles, CA.

November 4, 2016.

43. Hendifar, Andrew. Gastric Cancer. GI Fellows Lecture. Cedars-Sinai Medical Center. Los

Angeles, CA. December 1, 2016.

44. Hendifar, Andrew. Gastrointestinal Oncology: Pancreatic Cancers. Samuel Oschin

Comprehensive Cancer Institute (SOCCI) Multi-Disciplinary Tumor Board. Cedars-Sinai

Medical Center. Los Angeles, CA. January 11, 2017.


45. Hendifar, Andrew. Lymphoma/Leukemia. 3rd Year Inpatient Internal Medicine Student

Case-Based Didactic Session. Cedars-Sinai Medical Center. Los Angeles, CA. May 1, 2017.

46. Hendifar, Andrew. Using Precision Medicine to Treat and Study Pancreatic Cancer.

Gastrointestinal Grand Rounds Conference. Cedars-Sinai Medical Center. Los Angeles, CA.

May 18, 2017.

47. Hendifar, Andrew. Pancreatic Cancer & Nutrition. Cancer Support Community Los Angeles.

Los Angeles, CA. August 4, 2017.

48. Hendifar, Andrew. Pancreatic Cancer. Henry Mayo Newhall Hospital. Valencia, CA.

September 7, 2017.

49. Hendifar, Andrew. Oncologic Emergencies. 3rd Year Inpatient Internal Medicine Student

Case-Based Didactic Session. Cedars-Sinai Medical Center. Los Angeles, CA. October 30,

2017.

50. Hendifar, Andrew. IM/Hematology/Oncology: Neuroendocrine Carcinoma. Samuel Oschin

Comprehensive Cancer Institute (SOCCI) Molecular Tumor Board. Cedars-Sinai Medical

Center. Los Angeles, CA. November 1, 2017.

51. Hendifar, Andrew. Harnessing Her2/Neu, BRAF and MSI. 6th Annual Experimental

Therapeutics in Oncology: The Road to Personalized Medicine. Cedars-Sinai Medical Center.

Los Angeles, CA. November 4, 2017.

52. Hendifar, Andrew. Peptamen for Weight Loss. 10th International Society on Sarcopenia,

Cachexia and Wasting Disorders (SCWD) Conference on Cachexia, Sarcopenia & Muscle

Wasting. Rome, Italy. December 10, 2017.

53. Hendifar, Andrew. The Quest to Win Through Science in Pancreatic Cancer from

Sequencing Current Options to Testing Novel Approaches Dear Members. 2018 ASCO

Gastrointestinal Cancers Symposium. San Francisco, CA. January 19, 2018.

54. Hendifar, Andrew. Gastrointestinal Oncology: Gastrointestinal Cancer, Ectopic Producing

ACTH and Pancreatic Cancer. Samuel Oschin Comprehensive Cancer Institute (SOCCI)

Multi-Disciplinary Tumor Board. Cedars-Sinai Medical Center. Los Angeles, CA. March 7,

2018.

55. Hendifar, Andrew. Pancreas Cancer 2018. VA Sepulveda/Cedars-Sinai Medical Center

Grand Rounds. VA Sepulveda Ambulatory Care Center. North Hills, CA. March 8, 2018.

56. Hendifar, Andrew. Managing Symptoms—Carcinoid Syndrome & More. 2018 Annual Los

Angeles NET Patient Education Conference. UCLA. Los Angeles, CA. May 19, 2018.

57. Hendifar, Andrew. Pancreas Cancer 2018. Hematology/Oncology Grand Rounds.

Cedars-Sinai Medical Center. Los Angeles, CA. July 24, 2018.


58. Hendifar, Andrew. Neoplasms of the Stomach and Duodenum. GI Fellows Core Lecture.

Cedars-Sinai Medical Center. Los Angeles, CA. November 6, 2018.

TEACHING ACTIVITIES

1. 03/2013 Consult Service Attending Hematology and Oncology

2. 10/2013 Consult Service Attending Hematology and Oncology

3. 2013 – present Clinic Attending for Medical Students and Residents

4. 2013 – present Journal Club for Gastrointestinal (GI) Oncology

5. 10/2014 Surgical Oncology Fellowship Rotation in Gastrointestinal (GI)

Oncology, Fellow Jenny Hong

6. 2015 – present 3rd Year Inpatient Internal Medicine Student Case-Based Didactic

Sessions

7. 2015 – present Carcinoid and Neuroendocrine Tumor Board Meeting

8. 2015 – present Pancreatic Cancer Research Meeting

9. 06/05/2017 – 08/24/2017 Summer Intern Isaac Lapite

10. 06/27/2017 – 06/13/18 Intern Michelle Guan

11. 11/6/17 – 11/10/17 Surgical Oncology Fellowship Rotation in Gastrointestinal (GI)

Oncology, Fellow Jamie Green, MD

12. 12/01/17 – 02/27/18 Long Beach Polytechnic High School PACE Program (advanced

studies) Interns: Thomas Crahan and Jimmy Giles

MENTEES

Attendings

1. Patrick Yaffee, MD 07/2013 – 01/2015, one on one mentoring

Projects: Rectal cancer review, Th-302 in advanced soft tissue sarcoma

2. Carlyn Rose Tan, MD 01/2013 – 2016, one on one mentoring,

Projects: Pancreatic cancer cachexia, EGFRI inhibitors and colorectal cancer


3. Arsen Osipov, MD 07/2013 – present, one on one mentoring

Projects: Margin distance and lymph node stations in resected pancreatic cancer,

retrospective review of breast cancer gene (BRCA) mutated pancreatic cancer at Cedars

Sinai

Residents

4. Jasleen Khanuja, MD 01/2014 – 01/2016, one on one mentoring

Projects: Ethnicity and pancreatic cancer

5. Ingrid He, MD 08/17 – present, one on one mentoring

Projects: Tog 0631

6. Varun Roy, MD 09/17 – present, one on one mentoring

Projects: Portal hypertension in pancreatic cancer patients

PUBLIC RELATIONS

Media Partnerships

1. Hendifar, Andrew. Video Interview: PEGPH20 Survival Impact in High Hyaluronan

Pancreatic Cancer. OncLive, Oncology Specialty Group, Cranbury, NJ. Interviewer: Laura

Martin. 2015 ESMO World Congress on Gastrointestinal Cancer. Barcelona, Spain. July 1,

2015.

2. Hendifar, Andrew. Interview: I’m Drawn to Tough Challenges. Pancreatic Cancer Action

Network (PanCAN), Manhattan Beach, CA. April 26, 2017.

3. Hendifar, Andrew. Video Interview: “Breaking the barrier: a new therapeutic approach to the

treatment of pancreatic ductal adenocarcinoma.” Touch Medical Media, touch ONCOLOGY,

London. Interviewer: Joanna Brockley, Associate Editor of European Oncology and

Haematology. 2017 ASCO Annual Meeting. Chicago, IL. June 3, 2017.

4. Hendifar, Andrew. Video Interview: HALO-202 Study in Metastatic Pancreatic Ductal

Adenocarcinoma. OncLive, Oncology Specialty Group, Cranbury, NJ. Interviewer: Angelica

Welch, Assistant Web Editor. 2017 ESMO World Congress on Gastrointestinal Cancer.

Barcelona, Spain. June 29, 2017.

5. Hendifar, Andrew. Video Interview: Current Treatment Landscape in Pancreas Cancer.

OncLive TV, Cranbury, NJ. July 13, 2017.

6. Hendifar, Andrew. Cancer Radio Spot Recording. 740 Sound Design. Los Angeles, CA.

September 8, 2017.


7. Hendifar, Andrew. Video Interview: Molecular Classification of Neuroendocrine Tumors:

Clinical Experience with the 92-Gene Assay in 24,000 Cases. OncLive®, Cranbury, NJ.

Interviewer: Gina Columbus, Managing Editor, OncLive®. North American Neuroendocrine

Tumor Society (NANETS) 10th Annual Symposium. Philadelphia, PA. October 19, 2017.

8. Hendifar, Andrew. Video Interview: Molecular Classification Helps Pinpoint Subtype,

Origin of NETs. MDLinx, M3, Fort Washington, PA. Emergency Medicine. Interviewer: Liz

Meszaros, Sr. Medical Writer/Editor. North American Neuroendocrine Tumor Society

(NANETS) 10th Annual Symposium. Philadelphia, PA. October 19, 2017.

9. Hendifar, Andrew. Taped Interview: What’s on Your Mind? News Talk WMBS 590 AM /

101.1 FM. Host: Bill Madden. Estimated audience reach: 203,550 listeners. Pittsburgh, PA.

November 15, 2017.

10. Hendifar, Andrew. Taped Interview: Focus on Health Segment. News WGRT 102.3 FM.

Host: Cathie Martin, News Director. Estimated audience reach: 280,000 listeners. Detroit, MI.

November 15, 2017.

11. Hendifar, Andrew. Live Interview: The Good News. WDJC 93.7 FM. Host: Angie Austin.

Estimated national audience reach: 694,000 listeners. Birmingham, AL. November 15, 2017.

12. Hendifar, Andrew. Taped Interview. La Crosse Talk WIZM 1410 AM / 92.3 FM. Host: Mike

Hayes. Estimated audience reach: 197,750 listeners. La Crosse, WI. November 15, 2017.

13. Hendifar, Andrew. Taped Interview. Real Talk WSRB 106.3 FM / WYCA 102.3 FM. Host:

Debra Rhodes-Pettigrew. Estimated audience reach: 463,000 listeners. Chicago, IL. November

15, 2017.

Press Releases

1. Fitness trackers prove helpful in monitoring cancer patients. Los Angeles, CA: Cedars-Sinai

Medical Center Newsroom; July 24, 2018. Available at:

https://www.cedars-sinai.org/newsroom/fitness-trackers-prove-helpful-in-monitoring-cancer-

patients/. Accessed July 24, 2018.

2. Fitness trackers can help monitor cancer patients. Boston, MA: CBS; July 26, 2018. Available

at: https://boston.cbslocal.com/2018/07/26/fitness-trackers-monitor-cancer-patients/.

Accessed July 27, 2018.

3. Cedars-Sinai says fitness trackers prove helpful in monitoring cancer patients. Los Angeles,

CA: Los Angeles Tech News; July 26, 2018. Available at:

https://latechnews.org/cedars-sinai-says-fitness-trackers-prove-helpful-in-monitoring-cancer-

patients/. Accessed July 27, 2018.

https://www.cedars-sinai.org/newsroom/fitness-trackers-prove-helpful-in-monitoring-cancer-patients/

https://www.cedars-sinai.org/newsroom/fitness-trackers-prove-helpful-in-monitoring-cancer-patients/

https://boston.cbslocal.com/2018/07/26/fitness-trackers-monitor-cancer-patients/

https://latechnews.org/cedars-sinai-says-fitness-trackers-prove-helpful-in-monitoring-cancer-patients/

https://latechnews.org/cedars-sinai-says-fitness-trackers-prove-helpful-in-monitoring-cancer-patients/


4. Fitness trackers help monitor cancer patients. Hematology Times; July 25, 2018. Available at:

https://www.hematologytimes.com/section/related-issues/article/fitness-trackers-help-monito

r-cancer-patients/. Accessed July 27, 2018.

5. Fitness trackers could aid cancer patients. R&D Magazine; July 25, 2018. Available at:

https://www.rdmag.com/article/2018/07/fitness-trackers-could-aid-cancer-patients. Accessed

July 27, 2018.

6. Fitness trackers can benefit people in cancer treatment. HealthCentral; July 25, 2018.

Available at:

https://www.healthcentral.com/article/fitness-trackers-can-benefit-people-in-cancer-treatment.

Accessed July 27, 2018.

7. Fitness trackers helpful for cancer assessments. LabRoots; July 25, 2018. Available at:

https://www.labroots.com/trending/technology/12200/fitness-trackers-helpful-cancer-assess

ments. Accessed July 27, 2018.

8. Fitness trackers help assess quality of life, daily functioning during treatment: study. Los

Angeles, CA. Xinhua; July 25, 2018. Available at:

http://www.xinhuanet.com/english/2018-07/25/c_137346072.htm. Accessed July 27, 2018.

9. In patients with advanced cancer, fitness trackers may help assess performance status. AJMC;

August 1, 2018. Available at:

https://www.ajmc.com/focus-of-the-week/in-patients-with-advanced-cancer-fitness-trackers-

may-help-assess-performance-status. Accessed August 1, 2018.

10. Fitness trackers prove useful in supervising cancer patients. New York, NY: Healthcare News

24; July 27, 2018. Available at:

http://healthcarenews24.com/1125/fitness-trackers-prove-useful-in-supervising-cancer-patien

ts/. Accessed August 1, 2018.

BIBLIOGRAPHY/PUBLICATIONS

Research Papers (Peer-Reviewed)

A. Research Papers – Peer Reviewed

1. Hendifar, El-Khoueiry, Lenz. Targeting colorectal cancer. Hospital Pharmacy Europe. 2005

May/June;(20):50-53.

2. Hendifar AE, Johnson D, Arkfeld DG. Myositis ossificans: a case report. Arthritis Rheum.

2005 Oct 15;53(5):793-5. PubMed PMID: 16208662.

3. El-Khoueiry, Hendifar, Lenz. “The medical treatment of metastatic colorectal cancer.”

Oncology Special Edition. 2005;(8):211-216.

https://www.hematologytimes.com/section/related-issues/article/fitness-trackers-help-monitor-cancer-patients/

https://www.hematologytimes.com/section/related-issues/article/fitness-trackers-help-monitor-cancer-patients/

https://www.rdmag.com/article/2018/07/fitness-trackers-could-aid-cancer-patients

https://www.healthcentral.com/article/fitness-trackers-can-benefit-people-in-cancer-treatment

https://www.labroots.com/trending/technology/12200/fitness-trackers-helpful-cancer-assessments

https://www.labroots.com/trending/technology/12200/fitness-trackers-helpful-cancer-assessments

http://www.xinhuanet.com/english/2018-07/25/c_137346072.htm

https://www.ajmc.com/focus-of-the-week/in-patients-with-advanced-cancer-fitness-trackers-may-help-assess-performance-status

https://www.ajmc.com/focus-of-the-week/in-patients-with-advanced-cancer-fitness-trackers-may-help-assess-performance-status

http://healthcarenews24.com/1125/fitness-trackers-prove-useful-in-supervising-cancer-patients/

http://healthcarenews24.com/1125/fitness-trackers-prove-useful-in-supervising-cancer-patients/


4. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM,

Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Thymidylate

synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.

Pharmacogenet Genomics. 2008 Feb;18(2):161-8. doi:10.1097/FPC.0b013e3282f4aea6.

PubMed PMID: 18192902.

5. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA,

Nagashima F, Chang HM, Lenz HJ. Polymorphisms in VEGF and IL-8 predict tumor

recurrence in stage III colon cancer. Ann Oncol. 2008 Oct;19(10):1734-41. doi:

10.1093/annonc/mdn368. Epub 2008 Jun 11. PubMed PMID: 18550579.

6. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y,

Zhang W, Lenz HJ. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist

associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics. 2009

Feb;19(2):95-102. doi: 10.1097/FPC.0b013e32831a9ad1. PubMed PMID: 18987561.

7. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. Gender

disparities in metastatic colorectal cancer survival. Clin Cancer Res. 2009 Oct

15;15(20):6391-7. doi: 10.1158/1078-0432.CCR-09-0877. Epub 2009 Sep 29. PubMed PMID:

19789331.

8. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y,

Groshen S, Lenz HJ. Survival of metastatic gastric cancer: significance of age, sex and

race/ethnicity. J Gastrointest Oncol. 2011 Jun;2(2):77-84. doi:

10.3978/j.issn.2078-6891.2010.025. PubMed PMID: 22811834.

9. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C,

Menendez LR. A meta-analysis of osteosarcoma outcomes in the modern medical era.

Sarcoma. 2012;2012:704872. doi: 10.1155/2012/704872. Epub 2012 Mar 18. PubMed PMID:

22550423.

10. Andrew E Hendifar, Sant P Chawla. Pazopanib for nonadipocytic, non-GIST soft tissue

sarcomas. Community Oncology. 2012 Nov. 9(11):332–333.

11. Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YYM. Results of a

phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma

receiving doxorubicin and ifosfamide. BMC Cancer. 2013 Mar 16;13:121. doi:

10.1186/1471-2407-13-121. PubMed PMID: 23497336.

12. Gong J, Delioukina ML, Hendifar AE. A Rare Case of Primary Gastric HIV-Associated

peripheral t-cell lymphoma: relapsed disease treated with pemetrexed. World J Oncol. 2013

Oct;4(4-5):217-220. doi: 10.4021/wjon708w. Epub 2013 Sep 27. PubMed PMID: 29147360.


13. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N,

Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP. Randomised

phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in

translocation-related sarcomas. Eur J Cancer. 2014 Apr;50(6):1137-47. doi:

10.1016/j.ejca.2014.01.012. Epub 2014 Feb 7. PubMed PMID: 24512981.

14. Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR,

Hendifar AE, Kroll S, Ganjoo KN. Phase II Study of the safety and antitumor activity of the

hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced

soft tissue sarcoma. J Clin Oncol. 2014 Oct 10;32(29):3299-306. doi:

10.1200/JCO.2013.54.3660. Epub 2014 Sep 2. PubMed PMID: 25185097.

15. Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt

DJ. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015 Feb

15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13. PubMed PMID: 25312684.

16. Yang W, Reznik R, Fraass BA, Nissen N, Hendifar A, Wachsman A, Sandler H, Tuli R.

Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation

therapy for pancreatic cancer. Med Dosim. 2015 Spring;40(1):47-52. doi:

10.1016/j.meddos.2014.09.001. Epub 2014 Oct 22. PubMed PMID: 25445989.

17. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya

CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A,

Collisson EA. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas.

Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun

24. PubMed PMID: 26109333.

18. Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic

cancer. Mol Clin Oncol. 2016 Mar;4(3):315-325. Epub 2015 Dec 18. PubMed PMID:

26998283.

19. Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R. Influence of

body mass index and albumin on perioperative morbidity and clinical outcomes in resected

pancreatic adenocarcinoma. PLoS One. 2016 Mar 25;11(3):e0152172. doi:

10.1371/journal.pone.0152172. eCollection 2016. PubMed PMID: 27015568.

20. Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M,

Annamalai A, Nissen NN, Tuli R. Impact of margin status and lymphadenectomy on clinical

outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. J

Gastrointest Oncol. 2016 Apr;7(2):239-47. doi: 10.3978/j.issn.2078-6891.2015.109. PubMed

PMID: 27034792.


21. Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S,

Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E

3rd, Brody JR. A pilot study evaluating concordance between blood-based and

patient-matched tumor molecular testing within pancreatic cancer patients participating in the

Know Your Tumor (KYT) initiative. Oncotarget. 2016 Nov 8;8(48):83446-83456. doi:

10.18632/oncotarget.13225. eCollection 2017 Oct 13. PubMed PMID: 29137355.

22. Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE,

Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD,

Hochster HS. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients

with metastatic pancreatic cancer after prior therapy: SWOG S1115 Study Randomized

Clinical Trial. JAMA Oncol. 2016 Dec 15. doi: 10.1001/jamaoncol.2016.5383. [Epub ahead of

print] PMID: 27978579.

23. Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, Fan X. A clinicopathological

study of malignant insulinoma in a contemporary series. Pancreas. 2017 Jan;46(1):48-56.

PMID: 27984486.

24. Gong J, Sachdev E, Robbins LA, Lin E, Hendifar AE, Mita MM. Statins and pancreatic

cancer. Oncol Lett. 2017 Mar;13(3):1035-1040. doi: 10.3892/ol.2017.5572. Epub 2017 Jan 4.


25. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke

MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R,

Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J,

Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T,

Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase

3 Trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017 Jan

12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PubMed PMID: 28076709.

26. Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Identifying

prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images

for pancreatic cancer patients. J Gastrointest Oncol. 2017 Feb;8(1):127-138. doi:

10.21037/jgo.2016.12.04. PubMed PMID: 28280617.

27. Hendifar AE, Davies L, Tuli R. Private funding for pancreatic cancer research: more than a

chip shot. Gastroenterology. 2017 Apr;152(5):918-921.e2. doi: 10.1053/j.gastro.2017.02.034.

Epub 2017 Mar 1. PubMed PMID: 28259790.

28. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR,

Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS,

Herrmann K. Most of the intended management changes after (68)Ga-DOTATATE PET/CT

are implemented. J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450.

Epub 2017 May 4. PubMed PMID: 28473600.


29. Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS,

Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. Identification of targetable ALK

rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2017

May;15(5):555-562. PubMed PMID: 28476735.

30. Osipov A, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R.

Redefining the positive margin in pancreatic cancer: impact on patterns of failure, long-term

survival and adjuvant therapy. Ann Surg Oncol. 2017 Nov;24(12):3674-3682. doi:

10.1245/s10434-017-6076-z. Epub 2017 Sep 5. PubMed PMID: 28871564.

31. Manguso N, Johnson J, Harit A, Nissen N, Mirocha J, Hendifar A, Amersi F. Prognostic

factors associated with outcomes in small bowel neuroendocrine tumors. Am Surg. 2017 Oct

1;83(10):1174-1178. PubMed PMID: 29391119.

32. Gangi A, Siegel E, Barmparas G, Lo S, Jamil LH, Hendifar A, Nissen NN, Wolin EM, Amersi

F. Multifocality in small bowel neuroendocrine tumors. J Gastrointest Surg. 2017 Nov 8. doi:

10.1007/s11605-017-3586-8. [Epub ahead of print] PubMed PMID: 29119527.

33. Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R,

Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E,

Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Phase II Study of BEZ235

versus everolimus in patients with mammalian target of rapamycin inhibitor-naïve advanced

pancreatic neuroendocrine tumors. Oncologist. 2017 Dec 14. pii: theoncologist.2017-0144. doi:

10.1634/theoncologist.2017-0144. [Epub ahead of print] PubMed PMID: 29242283.

34. Yang G, Dhall D, Yu R, Tuli R, Amersi FF, Friedman ML, Nissen NN, Hendifar AE. The

clinicopathological aspects of primary presacral neuroendocrine neoplasms: one center

experience. Pancreas. 2018 Jan;47(1):122-129. doi:10.1097/MPA.0000000000000954.


35. Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS,

Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa

S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized phase II study of PEGPH20 plus

nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated,

metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018 Feb 1;36(4):359-366. doi:

10.1200/JCO.2017.74.9564. Epub 2017 Dec 12. PubMed PMID: 29232172.

36. Manguso N, Gangi A, Johnson J, Harit A, Nissen N, Jamil L, Lo S, Wachsman A, Hendifar A,

Amersi F. The role of pre-operative imaging and double balloon enteroscopy in the surgical

management of small bowel neuroendocrine tumors: Is it necessary? J Surg Oncol. 2018

Feb;117(2):207-212. doi: 10.1002/jso.24825. Epub 2017 Sep 20. PubMed PMID: 28940412.

37. Hendifar AE, Chang JI, Huang BZ, Tuli R, Wu BU. Cachexia, and not obesity, prior to

pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. J Gastrointest

Oncol. 2018 Feb;9(1):17-23. doi: 10.21037/jgo.2017.11.10. PubMed PMID: 29564167;

PubMed Central PMCID: PMC5848037.


38. Marchevsky AM, Hendifar A, Walts AE. The use of Ki-67 labeling index to grade pulmonary

well-differentiated neuroendocrine neoplasms: current best evidence. Mod Pathol. 2018 May

25. doi: 10.1038/s41379-018-0076-9. [Epub ahead of print] PubMed PMID: 29802361.

39. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday

T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E;

NETTER-1 Study Group. Health-related quality of life in patients with progressive midgut

neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial. J Clin

Oncol. 2018 Jun 7:JCO2018785865. doi: 10.1200/JCO.2018.78.5865. [Epub ahead of print]


40. Siref A, Balzer B, Hendifar A. Primary visceral merkel cell carcinoma: a case report and

review of the literature. Am J Dermatopathol. 2018 Jun 7. doi:

10.1097/DAD.0000000000001194. [Epub ahead of print] PubMed PMID: 29894357.

41. Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi

VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin

EF. Molecular profiling of pancreatic cancer patients: initial results from the Know Your

Tumor Initiative. Clin Cancer Res. 2018 Jun 28. pii: clincanres.0531.2018. doi:

10.1158/1078-0432.CCR-18-0531. [Epub ahead of print] PubMed PMID: 29954777.

42. Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK,

Biankin AV, Giordano H, Vonderheide RH, Domchek SM. Rucaparib monotherapy in patients

with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol.

2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16. PubMed PMID: 30051098.

43. Larson BK, Tuli R, Jamil LH, Lo SK, Deng N, Hendifar AE. Utility of endoscopic

ultrasound-guided biopsy for next-generation sequencing of pancreatic exocrine malignancies.

Pancreas. 2018 Jul 19. doi: 10.1097/MPA.0000000000001117. [Epub ahead of print] PubMed

PMID: 30028448.

44. Gresham G, Hendifar AE, Spiegel B, Neeman E, Tuli R, Rimel BJ, Figlin RA, Meinert CL,

Piantadosi S, Shinde AM. Wearable activity monitors to assess performance status and predict

clinical outcomes in advanced cancer patients. npj Digital Medicine (2018) 1:27;

doi:10.1038/s41746-018-0032-6.

45. Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, Barbie D, Hahn WC, Fuchs CS.

Phase 1 dose-escalation study of momelotinib, a Janus kinase ½ inhibitor, combined with

gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic

ductal adenocarcinoma. Invest New Drugs. 2018 Jul 30. doi: 10.1007/s10637-018-0650-5.

[Epub ahead of print] PubMed PMID: 30105668.


46. Hendifar AE, Dhall D, Strosberg JR. The evolving treatment algorithm for advanced

neuroendocrine neoplasms: diversity and commonalities across tumor types. Oncologist. 2018

Aug 13. pii: theoncologist.2018-0187. doi: 10.1634/theoncologist.2018-0187. [Epub ahead of

print] PubMed PMID: 30104288.

47. Hendifar AE, Delpassand ES, Kittleson MM, Tuli R. Cardiac toxicity in a patient receiving

peptide receptor radionuclide therapy. Pancreas. 2018 Sep;47(8):e55-e56. doi:

10.1097/MPA.0000000000001101. PubMed PMID: 30113434.

B. Research Papers – Peer Reviewed (In Press)

None

C. Research Papers – Peer Reviewed (Submitted)

None

Research Papers (Non-Peer-Reviewed)

D. Research Papers – Non-Peer Reviewed

None

E. Research Papers – Non-Peer Reviewed (In Press)

None

F. Research Papers – Non-Peer Reviewed (Submitted)

None

CHAPTERS

1. Sandy Liu, Andrew Hendifar, Edward Wolin. Novel Medical Treatments: Management of

Pancreatic Neuroendocrine Tumors. Springer. 2013.

2. Carlyn C Tan, Robert A Figlin, Andrew E Hendifar. The Evolving Role of Mammalian

Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma. mTOR Inhibition for

Cancer Therapy: Past, Present and Future. Springer. 2014:47.

3. Andrew E Hendifar, Sandy Liu, Edward Wolin. The Role of mTOR inhibitors in

Neuroendocrine Tumors. mTOR Inhibition for Cancer Therapy: Past, Present and Future.

Springer. 2014:93.

4. Osipov A, Tuli R, Hendifar A. Locally Advanced Pancreatic Cancer. Hematology-Oncology

Board Review Manual. 2017 May/June;12(3):14-28.


LETTERS TO THE EDITOR

None

REVIEWS

1. Hendifar AE, Ahlmann E, Allison DC, Hu J, Menendez L, Chawla SP. Moving beyond

response criteria: new measures of success in the treatment of sarcomas. Curr Treat Options

Oncol. 2012 Sep;13(3):299-305. doi: 10.1007/s11864-012-0197-1. Review. PubMed PMID:

22644834.

2. Reznik R, Hendifar AE, Tuli R. Genetic determinants and potential therapeutic targets for

pancreatic adenocarcinoma. Front Physiol. 2014 Mar 3;5:87. doi: 10.3389/fphys.2014.00087.

eCollection 2014. Review. PubMed PMID: 24624093.

3. Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, Tuli R, Hendifar AE. Pancreatic

cancer cachexia: a review of mechanisms and therapeutics. Front Physiol. 2014 Mar 3;5:88.

doi: 10.3389/fphys.2014.00088. eCollection 2014. Review. PubMed PMID: 24624094.

4. Hendifar A, Tan CR, Annamalai A, Tuli R. Biomarker-driven EGFR therapy improves

outcomes in patients with metastatic colorectal cancer. Expert Rev Anticancer Ther. 2014

Sep;14(9):1051-61. doi: 10.1586/14737140.2014.922881. Epub 2014 Jun 5. Review. PubMed

PMID: 24898788.

5. Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally

advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015 Apr;6(2):185-200. doi:

10.3978/j.issn.2078-6891.2014.112. Review. PubMed PMID: 25830038.

6. Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE. Targeting mTOR in

Pancreatic Ductal Adenocarcinoma. Front Oncol. 2016 Apr 25;6:99. doi:

10.3389/fonc.2016.00099. eCollection 2016. Review. PubMed PMID: 27200288.

7. Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current

challenges and advances in the diagnosis and management of well-differentiated disease. J

Thorac Oncol. 2017 Mar;12(3):425-436. doi: 10.1016/j.jtho.2016.11.2222. Epub 2016 Nov 24.

Review. PubMed PMID: 27890494.

8. Hendifar A, Bullock A. Breaking the barrier—PEGylated recombinant human hyaluronidase

(PEGPH20)—a new therapeutic approach to the treatment of pancreatic ductal

adenocarcinoma. Oncol Hematol. Review, 2017;13(2):107–11.

9. Gresham G, Schrack J, Gresham LM, Shinde AM, Hendifar AE, Tuli R, Rimel BJ, Figlin R,

Meinert CL, Piantadosi S. Wearable activity monitors in oncology trials: Current use of an

emerging technology. Contemp Clin Trials. 2017 Nov 9;64:13-21. doi:

10.1016/j.cct.2017.11.002. [Epub ahead of print] Review. PubMed PMID: 29129704.

10. Gong J, Wu D, Chuang J, Tuli R, Simard J, Hendifar A. Moving beyond conventional clinical

trial end points in treatment-refractory metastatic colorectal cancer: a composite quality-of-life

and symptom control end point. Clin Ther. 2017 Oct 24. pii: S0149-2918(17)30999-2. doi:

10.1016/j.clinthera.2017.09.015. [Epub ahead of print] Review. PubMed PMID: 29079389.


11. Gong J, Yan J, Forscher C, Hendifar A. Aldoxorubicin: a tumor-targeted doxorubicin

conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018 Apr

6;12:777-786. doi: 10.2147/DDDT.S140638. eCollection 2018. Review. PubMed PMID:

29670334; PubMed Central PMCID: PMC5896668.

12. Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1

blockade: the clinical development of an evolving anticancer combination. J Immunother

Cancer. 2018 Jun 4;6(1):46. doi: 10.1186/s40425-018-0361-7. Review. PubMed PMID:

29866197.

13. Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Combination

systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming

resistance to single-agent checkpoint blockade. Clin Transl Med. 2018 Oct 8;7(1):32. doi:

10.1186/s40169-018-0210-9. Review. PubMed PMID: 30294755; PubMed Central PMCID:

PMC6174117.

EDITORIALS

None

PAPERS IN PREPARATION (RESEARCH COMPLETED)

None

ABSTRACTS

1. Hendifar, Kortes, Blumenthal. Varying mechanisms of influenza hemaglutinin–mediated

conformational change. National Institutes of Health: Poster Day, August 1996. Bethesda,

MD.

2. Hendifar, Kortes, Blumenthal. Conformational changes and fusion activity mediated by

influenza hemaglutinin. National Institutes of Health: Poster Day, August 1997. Bethesda,

MD.

3. Hendifar, Fisher, DeSalvo. Warning: exposure to violence may be hazardous to your health.

2003 Society of General Internal Medicine 26th Annual Meeting. Vancouver, BC, Canada.

4. Hendifar, Zhang, Yang, Igbal, Lenz. Polymorphisms of transforming growth factor-beta 1

and recurrence in stage II and III colon cancer. 2005 American Society of Clinical Oncology

(ASCO) Annual Meeting, May 13-17. Orlando, FL.

5. Yeramian, Hendifar, Brynes, Johnson. Hemophagocytic lymphohistiocytosis: a fatal

presentation of HIV and fever of unknown origin (FUO). 2005 American College Physicians

National Conference. Philadelphia, PA.


6. G Lurje, AM Schultheis, AE Hendifar, S Ashouri, W Zhang, MA Gordon, F Nagashima, HM

Chang, D Yang, HJ Lenz. VEGF and VEGF receptor-2 (VEGFR2) gene polymorphisms

predict tumor recurrence in stage II and III colon cancer. 2007 ASCO Annual Meeting, June

1-5. Chicago, IL.

7. G Lurje, W Zhang, D Yang, H Husain, AE Hendifar, Ashouri, A Pohl, Y Ning, S Iqbal, A

El-Khoueiry, HJ Lenz. Polymorphisms in interleukin-1 (IL-1B) and IL-1 receptor antagonist

(IL-1Ra) predict tumor recurrence in stage II colon cancer. 2008 Gastrointestinal Cancers

Symposium, January 25-27. Orlando, FL.

8. AE Hendifar, G Lurje, F Lenz, A Pohl, PC Manegold, K Togawa, H Husain, HJ Lenz, D Yang.

Sex, age, and ethnicity are associated with survival in metastatic colorectal cancer. 2008

ASCO Annual Meeting, May 30-June 3. Chicago, IL. J Clin Oncol. 2008 May 20;26 (15

suppl):4015-4015. (PD)

9. H Husain, G Lurje, D Yang, W Zhang, AE Hendifar, S Ahouri, A Pohl, PC Manegold, S Iqbal,

A El-Khoueiry, H Lenz. Ethnicity is associated with recurrence in patients with resected

gastric cancer. 2008 ASCO Annual Meeting, May 30-June 3. Chicago, IL. (PP)

10. AE Hendifar, D Yang, S Iqbal, H Lenz, A El-Khoueiry. Gender Disparities in hepatocellular

cancer survival. 2009 ASCO Annual Meeting, May 29-June 2. Orlando, FL.

11. J Kim, A Hendifar, D Cao, A Jeng, R Haile. Low rate of screening and surveillance

colonoscopies is associated with advanced colorectal cancer in an urban safety-net hospital.

2009 AGA Institute Clinical Research in Colon Cancer, September 17-19. Chicago, IL.

12. S Lieskovan, A Hendifar, S Ahmed, T Rawi, B Chaudry. A case of warm-antibody

autoimmune hemolytic anemia without spherocytosis. 2009 ACP Regional Conference. Los

Angeles, CA.

13. A Chen, C Lazaro, R Gupta, R Jain, A Hendifar, V Chua, S Chawla. A phase II study of low

dose gemzar, taxotere and adriamycin (TAG) regimen in patients with metastatic soft tissue

sarcomas and failure to prior chemotherapy. 2010 CTOS Annual Meeting, November 11-13.

Paris, France.

14. SP Chawla, CB Lazaro, A Hendifar, RR Gupta, R Rana, R Nadadur, PRG, VS Chua. A phase

II study of VEGF-AS veglin with pemetrexed and cisplatin, CAV regimen, in the treatment of

patients with malignant mesothelioma. 2010 Chicago Multidisciplinary Symposium in

Thoracic Oncology, December 9-11. Chicago, IL. J Thorac Oncol. 2010 Dec;5(12):S529-S529

(suppl 7; abstract 155). (PP)

15. Andrew Hendifar, Shelly Chawla, Vicky Chua, Lita Fernandez, Bartosz Chiemelowski,

James Hu, and Sant Chawla. 14 day continuous infusion high-dose ifosfamide in adolescent

and adult sarcoma patients. 2011 Combined Meeting of the Connective Tissue Oncology

Society and the Musculoskeletal Tumor Society, October 26-29. Chicago, IL. (PP #77)


16. Andrew E. Hendifar, SP Chawla, D Quon, VS Chua, L Fernandez, S Nagre, M Okunnu, B

Chmielowski, AS. Singh, S Akmaev, D Chatman, J McCook, Shen Luan, Rangaprasad

Sarangarajan, Paul Y. Song, Niven R Narain. Phase I study of BPM 31510 in advanced solid

tumors: Updated analysis of a novel treatment with promising activity. 2012 ASCO Annual

Meeting, June1-5. Chicago, IL. J Clin Oncol 30, 2012 (suppl; abstr 3015).

17. SP Chawla, V Chua, AE Hendifar, D Quon, S Nagre, KN Ganjoo, K Sankhala, S Wieland, D

Levitt. Phase Ib/II study of INNO-206 (EMCH-doxorubicin) in patients with soft tissue

sarcoma. 2012 ASCO Annual Meeting, June1-5. Chicago, IL. J Clin Oncol 30, 2012 (suppl;

abstr 10036).

18. SP Chawla, VS Chua, A Hendifar, D Quon, S Negre, KN Ganjoo, K Sankhala, Y Lavinski, S

Wieland, D Levitt. INNO-206 is an active drug for+ relapsed advanced soft tissue sarcoma.

2012 ESMO Congress, September 28-October 2. Vienna, Austria. (1483PD)

19. Kristen N Ganjoo, Lee Cranmer, Brian Van Tine, Andrew Hendifar, Esther D Chu, Stew

Kroll, Sant P Chawla. Th-302 maintenance following Th-302 plus doxorubicin induction: the

results of a phase 2 study of TH-302 in combination with doxorubicin in soft tissue sarcoma.

2012 Connective Tissue Oncology Society Annual Meeting, November 14-17. Prague, Czech

Republic.

20. Sant Chawla, Victoria Chua, Andrew Hendifar et al. Aldoxorubin is an active drug for the

treatment of soft tissue sarcoma. 2012 Connective Tissue Oncology Society Annual Meeting,

November 14-17. Prague, Czech Republic.

21. Sant P Chawla, Vivek Narasimhan, Andrew E Hendifar et al. Low dose gemcitabine,

doxorubicin, and docetaxel combination in patients with advanced, unresectable, and/or

metastatic sarcoma who had failed prior chemotherapy, an updated analysis. 2012 Connective

Tissue Oncology Society Annual Meeting, November 14-17. Prague, Czech Republic.

22. Sant P Chawla, Harsha Rajashekharaiah, Andrew E Hendifar et al; Continuous infusion of

high dose ifosfamide in adolescents and adults with soft tissue sarcoma. 2012 Connective

Tissue Oncology Society Annual Meeting, November 14-17. Prague, Czech Republic.

23. Hendifar, A. Results of the randomized phase III trial of trabectedin (T) versus

doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with

translocation-related sarcoma (TRS). 2013 ASCO Annual Meeting, May 31-June 4. Chicago,

IL. J Clin Oncol 31, 2013 (suppl; abstr 10517). (PD)

24. Alexandra Gangi, Vijay G. Menon, Marwan Sheckley, Richard Tuli, Andrew Eugene

Hendifar, Ashley Wachsman, Nicholas N. Nissen. Recurrence of pancreatic ductal

adenocarcinoma after pancreaticoduodenectomy: Is there a role for locoregional treatment?

2014 Gastrointestinal Cancers Symposium, January 16-18. San Francisco, CA. J Clin Oncol

32, 2014 (suppl 3; abstr 329). (GPS)


25. Richard Tuli, Benedick Fraass, Wensha Yang, Howard Mark Sandler, Andrew Hendifar,

Nicholas N. Nissen, Yong Yue. Pretreatment [18F] FDG-PET texture analysis to predict local

response of pancreatic cancer to radiotherapy. 2014 Gastrointestinal Cancers Symposium,

January 16-18. San Francisco, CA. J Clin Oncol 32, 2014 (suppl 3; abstr 375) (GPS)

26. Richard Tuli, Wensha Yang, Mourad Tighiouart, Yong Yue, Benedick Fraass, Howard Mark

Sandler, Andrew Eugene Hendifar, Nicholas N. Nissen. 18F-FDG PET as a predictor of

resectability and clinical outcomes in locally advanced pancreatic cancer patients treated with

radiotherapy. 2014 Gastrointestinal Cancers Symposium, January 16-18. San Francisco, CA. J

Clin Oncol 32, 2014 (suppl 3; abstr 378). (GPS)

27. Susan M Domchek, Robert McWilliams, Andrew Hendifar, Rachna T Shroff, Lawrence

Leichman, Ron Epelbaum, Ravit Geva, George Kim, Steven R Alberts, Robert A Wolff,

Andrew Allen, Heidi Giordano, Mitch Raponi, Jeff Isaacson, Lindsey Rolfe, Andrew Biankin,

Robert H Vonderheide. A phase 2, open-label study of the PARP inhibitor rucaparib in patients

with pancreatic cancer and a known deleterious BRCA mutation. 2014 AACR Pancreatic

Cancer: Innovations in Research and Treatment, May 18-21. New Orleans, LA. Cancer Res.

2015 June 30;75(13 Supplement):B102-B102.

28. Andrew Eugene Hendifar, Carlyn Rose Co Tan, Patrick Yaffee, Arsen Osipov, Richard Tuli,

Christie Y Jeon. Evaluating outcomes of pancreatic cancer patients with cacehxia. 2014 ASCO

Annual Meeting, May 30-June 3. Chicago, IL. J Clin Oncol 32, 2014 (suppl; abstr e15208).

29. Carlyn Rose Co Tan, Rhonda Aizenberg, Lynne Davies, Lynn Matrisian, Xiao Zhang, Richard

Tuli, Andrew Eugene Hendifar. The shifting landscape of pancreatic cancer research funding.

2014 ASCO Annual Meeting, May 30-June 3. Chicago, IL. J Clin Oncol 32, 2014 (suppl; abstr

e17545).

30. Susan M Domchek, Robert R McWilliams, Andrew Eugene Hendifar, Rachna T Shroff,

Lawrence P Leichman, Ron Epelbaum, Ravit Geva, George P Kim, Steven R Alberts, Robert

A Wolff, Andrew R Allen, Heidi Giordano, Mitch Raponi, Jeffrey D Isaacson, Lindsey Rolfe,

Andrew Biankin, Robert H Vonderheide. A phase 2, open-label study of rucaparib in patients

with pancreatic cancer and a known deleterious BRCA mutation. 2014 ASCO Annual Meeting,

May 30-June 3. Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4161).

31. Andrew E Hendifar, Sue Swain, Loni Lee, Jasleen Khanuja, Arsen Osipov, Nick Nissen,

Richard Tuli. A study of rucaparib in patients with pancreatic cancer and a known deleterious

BRCA mutation. 2014 20th Anniversary BRCA Gene Symposium: Advances in Care for the

New Millennium, September 13. Los Angeles, CA.

32. Andrew Hendifar, Nicholas Nissen, David Hoffman, Stephen Miles, Miranda Bryant,

Mourad Tighiouart, Andre Rogatko, Simon Lo, Ashley Wachsman, Arsen Osipov, Richard

Tuli. Phase I study of veliparib with gemcitabine and radiation therapy in patients with locally

advanced unresectable pancreatic cancer. 2014 20th Anniversary BRCA Gene Symposium:

Advances in Care for the New Millennium, September 13. Los Angeles, CA.


33. A Hendifar, Jasleen Khanuja, Gillian Gresham, Arsen Osipov, Carlyn-Rose Tan, Richard Tuli.

Treatment and underlying mechanisms of pancreatic cancer cachexia. 2014 2nd Cancer

Cachexia Conference: Evolving Mechanisms and Therapies, September 26-28. Montreal,

Canada.

34. Andrew Hendifar, Arsen Osipov, Jason Naziri, Wensha Yang, Nicholas Nissen, Richard Tuli.

Body Mass Index and Outcomes in a Cohort of Resected Pancreatic Cancer Patients. 2014

American Pancreatic Association & Japan Pancreas Society Annual Meeting, November 5-8.

Waimea, Big Island, HI.

35. Jasleen Khanuja, Gillian Gresham, Arsen Osipov, Richard Tuli, Andrew Eugene Hendifar.

Treatment and underlying mechanisms of pancreatic cancer cachexia (PANCAX study). 2015

Gastrointestinal Cancers Symposium, January 15-17. San Francisco, CA. J Clin Oncol 33,

2015 (suppl 3; abstr TPS491).

36. Arsen Osipov, Jason Naziri, Andrew Eugene Hendifar, Deepti Dhall, Joanne K Rutgers,

Shefali Chopra, Quanlin Li, Alagappan Annamalai, Mourad Tighiouart, Nicholas N Nissen,

Richard Tuli. Impact of margin status and lymphadenectomy on clinical outcomes in resected

pancreatic cancer: implications for adjuvant radiotherapy. 2015 Gastrointestinal Cancers

Symposium, January 15-17. San Francisco, CA. J Clin Oncol 33, 2015 (suppl 3; abstr 429).

37. S Libutti, R Garcia-Carbonero, EM Wolin, A Custodio, JC Yao AE Hendifar, R Tavorath, N

Mukherjee, F Herbst, J Sulovski, R Salazar. CBEZ235Z2401: Randomized phase II study of

BEZ235 or everolimus (EVE) in patients with advanced pancreatic neuroendocrine tumors

(pNET). ENETS, 2015 12th Annual Conference for the Diagnosis and Treatment of

Neuroendocrine Tumor Disease, March 11-13. Barcelona, Spain. Neuroendocrinology. 2015

102:131-131

38. Andrew Eugene Hendifar, Xiao Zhang, Rhonda Aizenberg, Mila McCurrach, Pat Morin,

Richard Tuli, Lynn Matrisian, Lynne Davies. A quantitative analysis of funding for pancreatic

cancer research. 2015 ASCO Annual Meeting, May 29-June 2. Chicago, IL. J Clin Oncol 33,

2015 (suppl; abstr 4126).

39. Andrew Eugene Hendifar, Neal S Chawla, Kamalesh Kumar Sankhala, Xiao Zhang, Doris V.

Quon, Victoria S Chua, Lita Fernandez, William E. Mendanha, Sant P. Chawla. Phase 2 study

of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or

metastatic sarcoma who have failed prior therapies. 2015 ASCO Annual Meeting, May

29-June 2. Chicago, IL. J Clin Oncol 33, 2015 (suppl; abstr 10573).

40. Arsen Osipov, Jasleen Khanuja, Quanlin Li, Jason Naziri, Andrew Eugene Hendifar,

Richard Tuli. The influence of body mass index and albumin on perioperative morbidity and

clinical outcomes in resected pancreatic adenocarcinoma. 2015 ASCO Annual Meeting, May

29-June 2. Chicago, IL. J Clin Oncol 33, 2015 (suppl; abstr e15210).


41. Sunil R. Hingorani, William Proctor Harris, Andrew Eugene Hendifar, Andrea J. Bullock,

Xionghua W. Wu, Ya Huang, Ping Jiang. High response rate and PFS with PEGPH20 added to

nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with

high-HA tumors: interim results of a randomized phase II study. 2015 ASCO Annual Meeting,

May 29-June 2. Chicago, IL. J Clin Oncol 33, 2015 (suppl; abstr 4006).

42. A. Hendifar, S. Hingorani, W. Harris, T. Seery, D. Sigal, W. Wu, S. Dychter, P. Jiang. High

response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV

previously untreated pancreatic cancer patients with high-HA tumors: interim results of a

randomized phase 2 study. 2015 ESMO World Congress on Gastrointestinal Cancer, July 1-4.

Barcelona, Spain. Ann Oncol. 2015 June;26(suppl_4):iv117. (LBA 02)

43. J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, RP Baum, E Mittra, T

Hobday, A Hendifar, K Oberg, M Lopera Sierra, P Ruszniewski, D Kwekkeboom..

177-Lu-Dotatate significantly improves progression-free survival in patients with midgut

neuroendocrine tumours: results of the phase III NETTER-1 trial. 2015 European Cancer

Congress, September 25-29. Vienna, Austria. (LBA 6) (Presidential Session)

44. S Hingorani, W Harris, A Hendifar, A Bullock, X Wu, Y Huang, P Jiang, D Von Hoff. High

response rate and progression free survival with PEGylated recombinant human hyaluronidase

added to Nab-Paclitaxel/ Gemcitabine in stage IV previously untreated pancreatic cancer

patients with high-HA tumors: interim results of a randomized phase 2 study. 2015 European

Cancer Congress, September 25-29. Vienna, Austria. Eur J Cancer. 2015

September;51(3):S439–S440. (suppl; abstr 2321) (PS)

45. A. Baecker, S.J. Pandol, A. Hendifar, N. Nissen, B. Wu, C.Y. Jeon. Applying healthcare

utilization data to predict pancreatic cancer. 2015 American Pancreatic Association Annual

Meeting, November 4-7. San Diego, CA. Pancreas. 2015 November;44(8):1358–1430.

46. Anitra Engebretson, Jonathan Robert Brody, Lola Rahib, Lynn Matrisian, Andrew Eugene

Hendifar, William Arthur Hoos, Sameh Mikhail, Vincent M Chung, Vincent J Picozzi, Craig

Heartwell, Kimberly Mason, Katelyn Varieur, Subha Madhavan, Emanuel Petricoin, Michael

J Pishvaian. The Know Your Tumor (KYT) initiative: a national program of multi-omic

molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA). 2016


2016 (suppl 4S; abstr 279). (PS)

47. Michael J Pishvaian, Lynn Matrisian, Andrew Eugene Hendifar, Anitra Engebretson, Lola

Rahib, William Arthur Hoos, Sameh Mikhail, Vincent M Chung, Vincent J Picozzi, Craig

Heartwell, Kimberly Mason, Katelyn Varieur, Subha Madhavan, Emanuel Petricoin, Jonathan

Robert Brody. Preliminary observations of blood-based (BB) molecular testing in a subset of

patients with pancreatic cancer (PDA) participating in the Know Your Tumor (KYT) initiative.


34, 2016 (suppl 4S; abstr 268). (PS)


48. Sanjay Goel, Lucjan Wyrwicz, Minsig Choi, Andrew L Coveler, Antonio Ucar, Alexander

Ward Brown, Tomasz Sarosiek, Lucas Wong, Michael Stecher, George A Fisher, Andrew

Eugene Hendifar. Phase III double-blinded, placebo-controlled study of MABp1 for

improving survival in metastatic colorectal cancer. 2016 Gastrointestinal Cancers Symposium,

January 21-23. San Francisco, CA. J Clin Oncol 34, 2016 (suppl 4S; abstr TPS784).

49. Richard Tuli, Nicholas N Nissen, Alagappan Annamalai, David MJ Hoffman, Miranda Bryant,

Mourad Tighiouart, Andre Rogatko, Sepehr Rokhsar, Kevin S Scher, Laith Jamil, Simon Lo,

Andrew Eugene Hendifar. Phase I study of veliparib with gemcitabine and radiation therapy

in patients with borderline resectable and locally advanced unresectable pancreatic cancer.


34, 2016 (suppl 4S; abstr TPS487).

50. Jonathan R Strosberg, Edward M Wolin, Beth Chasen, Matthew H Kulke, David L Bushnell,

Martyn E Caplin, Richard P Baum, Pamela L Kunz, Timothy J Hobday, Andrew Eugene

Hendifar, Kjell E Oberg, Maribel Lopera Sierra, Dik J Kwekkeboom, Philippe B Ruszniewski,

Eric Krenning. NETTER-1 phase III: Progression-free survival, radiographic response, and

preliminary overall survival results in patients with midgut neuroendocrine tumors treated with

177-Lu-Dotatate. 2016 Gastrointestinal Cancers Symposium, January 21-23. San Francisco,

CA. J Clin Oncol 34, 2016 (suppl 4S; abstr 194). (PS)

51. Michael J Pishvaian, Jonathan Robert Brody, Lynn Matrisian, Andrew Eugene Hendifar,

Anitra Engebretson, William Arthur Hoos, Sameh Mikhail, Vincent M Chung, Vincent J

Picozzi, Corinne Ramos, Craig Heartwell, Kimberly Mason, Katelyn Varieur, Lola Rahib,

Emanuel Petricoin, Subha Madhavan. Multi-Omic profiling (MoP) for patients (pts) with

pancreatic cancer (PDA): initial results of the Know Your Tumor (KYT) initiative. 2016



52. Sunil R Hingorani, William Proctor Harris, Tara Elisabeth Seery, Lei Zheng, Darren Sigal,

Andrew Eugene Hendifar, Fadi S Braiteh, Mark Zalupski, Ari David Baron, Nathan Bahary,

Andrea Wang-Gillam, Noelle K LoConte, Gregory M Springett, Paul S Ritch, Aram F Hezel,

Wen Wee Ma, Venu Gopal Bathini, Xionghua W Wu, Ping Jiang, Andrea J Bullock. Interim

results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in

patients with stage IV previously untreated pancreatic cancer. 2016 Gastrointestinal Cancers

Symposium, January 21-23. San Francisco, CA. J Clin Oncol 34, 2016 (suppl 4S; abstr 439).

(PS)

53. Jeffrey Toll, Arsen Osipov, Jasleen Khanuja, Dana Pan, Rishi Patel, Jenny Zhou, Arvind

Manohar Shinde, Alagappan Annamalai, Andrew Eugene Hendifar, Richard Tuli. DNA

sequencing to identify potentially novel targets for therapy in pancreatic cancer. 2016




54. Eve Makoff, Arvind Manohar Shinde, Richard Tuli, Andrew Eugene Hendifar. Panc Support

Project (PSP): evaluating the integration of palliative care into a pancreatic cancer program at a

comprehensive cancer center. 2016 ASCO Quality Care Symposium, February 26-27. Phoenix,

AZ. J Clin Oncol 34, 2016 (suppl 7S; abstr 241). (PS)

55. Arvind Manohar Shinde, Azadeh Dashti, Eve Makoff, Navasard Ovasapians, Andrew Eugene

Hendifar, Richard Tuli, Robert A Figlin. MD and RN ECOG-PS assessments prior to

chemotherapy and concordance rates: a quality initiative at a comprehensive cancer center.

2016 ASCO Quality Care Symposium, February 26-27. Phoenix, AZ. J Clin Oncol 34, 2016

(suppl 7S; abstr 228).

56. Andrea J Bullock, Sunil R Hingorani, Xionghua W Wu, Ping Jiang, Dimitrios Chondros,

Sihem Khelifa, Carrie Aldrich, Jie Pu, Andrew Eugene Hendifar. Final analysis of stage 1

data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage

IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion

diagnostic assay. 2016 ASCO Annual Meeting, June 3-7. Chicago, IL. J Clin Oncol 34, 2016

(suppl; abstr 4104). (PS)

57. Jeffrey Toll, Quanlin Li, Arsen Osipov, Jenny Zhou, Rishi Patel, Dana Pan, Jasleen Khanuja,

Miranda Bryant, Richard Tuli, Andrew Eugene Hendifar. Identifying novel genetic

alterations for risk stratification and prognostication in pancreatic cancer. 2016 ASCO Annual

Meeting, June 3-7. Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr e15754).


Martyn E Caplin, Richard P Baum, Timothy J Hobday, Andrew Eugene Hendifar, Kjell E

Oberg, Maribel Lopera Sierra, Dik J Kwekkeboom, Philippe B Ruszniewski, Eric Krenning,

Pamela L Kunz. NETTER-1 phase III: efficacy and safety results in patients with midgut

neuroendocrine tumors treated with 177Lu-Dotatate. 2016 ASCO Annual Meeting, June 3-7.

Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4005). (OAS)

59. Arsen Osipov, Joanne K Rutgers, Deepti Dhall, Jason Naziri, Shefali Chopra, Quanlin Li,

Nicholas N Nissen, Richard Tuli, Andrew Eugene Hendifar. Redefining the positive margin

in pancreatic cancer: impact of distance on survival. 2016 ASCO Annual Meeting, June 3-7.

Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4122). (PS)

60. Susan M Domchek, Andrew Eugene Hendifar, Robert R McWilliams, Ravit Geva, Ron

Epelbaum, Andrew Biankin, Robert H Vonderheide, Robert A Wolff, Steven R Alberts, Heidi

Giordano, Sandra Goble, Kevin K Lin, Rachna T Shroff. RUCAPANC: An open-label, phase

2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a

known deleterious germline or somatic BRCA mutation. 2016 ASCO Annual Meeting, June

3-7. Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4110). (PS)


61. Arvind Manohar Shinde, Gillian K Gresham, Andrew Eugene Hendifar, Richard Tuli,

Brennan Spiegel, Robert A Figlin. Biosensors to assess performance status in cancer (BioAPS

Study). 2016 ASCO Annual Meeting, June 3-7. Chicago, IL. J Clin Oncol 34, 2016 (suppl;

abstr TPS6631). (PS)

62. S Hingorani, A Bullock, W Harris, W Wu, P Jiang, D Chondros, S Khelifa, C Aldrich, J Pu, A

Hendifar. Final analysis of stage 1 data from a randomized phase 2 study of PEGPH20 plus

nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients,

utilizing Ventana companion diagnostic assay. 2016 ESMO World Congress on

Gastrointestinal Cancer, June 29-July 2. Barcelona, Spain. Ann Oncol. 2016

June;27(suppl_2):ii103. (PD 006)

63. J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, R Baum, P Kunz, T Hobday,

K Oberg, M Lopera Sierra, D Kwekkeboom, P Ruszniewski, E Krenning, A Hendifar.

NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine

tumors treated with 177Lu-Dotatate. 2016 ESMO World Congress on Gastrointestinal Cancer,

June 29-July 2. Barcelona, Spain. Ann Oncol. 2016 June;27(suppl_2):ii121. (O 009)

64. E Van Cutsem, AE Hendifar, M Reni, WP Harris, M Ducreux, A Bullock, P Corrie, V

Heinemann, T Seery, D Chondros, L Zheng. Global phase 3, randomized, double-blind,

placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20

(PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated,

hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma. 2016 ESMO World

Congress on Gastrointestinal Cancer, June 29-July 2. Barcelona, Spain. Ann Oncol. 2016

Oct.;27(suppl_6):715TiP.

65. J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, R Baum, PL Kunz, T

Hobday, A Hendifar, K Oberg, M Lopera Sierra, D Kwekkeboom, P Ruszniewski, E

Krenning. NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with

177Lu-Dotatate: efficacy, safety, QOL results and subgroup analysis. 2016 ESMO World

Congress on Gastrointestinal Cancer, June 29-July 2. Barcelona, Spain. Ann Oncol. 2016

Oct.;27(suppl_6):420PD.

66. Tempero, Margaret; Hingorani Sunil; Zheng, Lei; Reni, Michele; Hendifar, Andrew;

Ducreux, Michel; Bullock, Andrea; Corrie, Pippa; Harris, William; Heinemann, Volker; Seery,

Tara; Wu, Wilson; Chondros, Dimitrios; Van Cutsem, Eric. Global Phase 3, Randomized,

double-blind, placebo-controlled, multicenter study to compare efficacy and safety of

PEGylated recombinant human hyaluronidase (PEGPH20) plus nab-paclitaxel and

gemcitabine vs. placebo plus nab-paclitaxel and gemcitabine. 2016 ESMO World Congress on

Gastrointestinal Cancer, June 29-July 2. Barcelona, Spain. Ann Oncol. 2016

June;27(suppl_2):ii84. (P 288)


67. Brent K Larson, Dana Pan, Jasleen Khanuja, Rishi Patel, Jenny Zhou, Arsen Osipov, Maha

Guindi, Thomas Müller, Quanlin Li, Ping Jiang, Richard Tuli, Andrew Eugene Hendifar.

Association of hyaluronan accumulation with clinical-pathologic features in pancreatic ductal

adenocarcinomas. 2017 Gastrointestinal Cancers Symposium, January 19-21. San Francisco,

CA. J Clin Oncol 35, 2017 (suppl 4S; abstract 322). (PS)

68. R Joseph Bender, David Halverson, Kimberly Mason, Linlin Luo, Jonathan Robert Brody,

Lola Rahib, Lynn McCormick Matrisian, Andrew Eugene Hendifar, William Arthur Hoos,

Sameh Mikhail, Vincent M Chung, Vincent J Picozzi, Corinne Ramos, Craig Heartwell,

Katelyn Varieur, Metasebia Aberra, Emanuel Petricoin, Subha Madhavan, Michael J

Pishvaian. Molecular biomarkers as predictors of patient survival in pancreatic

adenocarcinoma (PDA): an analysis of the Know Your Tumor initiative (KYT). 2017


2017 (suppl 4S; abstract 278). (PS)


Martyn E Caplin, Richard P Baum, Pamela L Kunz, Timothy J Hobday, Andrew Eugene

Hendifar, Kjell E Oberg, Maribel Lopera Sierra, Dik J Kwekkeboom, Philippe B Ruszniewski,

Eric Krenning. Quality-of-life findings in patients with midgut neuroendocrine tumors: results

of the NETTER-1 phase III trial. 2017 Gastrointestinal Cancers Symposium, January 19-21.

San Francisco, CA. J Clin Oncol 35, 2017 (suppl 4S; abstract 348). (PS)

70. Brent K Larson, Nan Deng, Richard Tuli, Andrew Eugene Hendifar. Utility of endoscopic

ultrasound-guided biopsy for genomic analysis of pancreatic exocrine malignancies. 2017


2017 (suppl 4S; abstract 423). (PS)

71. Rishi Patel, R Joseph Bender, Quanlin Li, Dana Pan, Richard Tuli, Michael J. Pishvaian,

Andrew Eugene Hendifar. Multi-omic molecular profiling of pancreatic neuroendocrine

tumors. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017 (suppl;

abstr e 15685).

72. Gillian K. Gresham, Elad Neeman, Andrew Eugene Hendifar, Quanlin Li, Richard Tuli, Bj

Rimel, Christine S. Walsh, Brennan Spiegel, Robert A. Figlin, Steven Piantadosi, Arvind

Manohar Shinde. Assessing performance status and clinical outcomes with wearable activity

monitors. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017 (suppl;

abstr 6571). (PS Board #393)

73. Andrew Eugene Hendifar, Harris S Soifer, Mason Israel, Catherine A. Schnabel. Molecular

classification of neuroendocrine tumors: Clinical experience with the 92-gene assay

in >24,000 cases. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017

(suppl; abstr e 15700).


74. Arsen Osipov, Quanlin Li, Shant Thomassian, Lakshmanan Annamalai, Jennifer Holmes

Yearley, Joanne K Rutgers, Andrew Eugene Hendifar, Richard Tuli. Impact of

chemoradiotherapy on PD1/PDL1 expression and clinical outcomes in gastroesophageal

cancers. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017 (suppl;

abstr 4031). (PS Board #23)

75. Nicholas Manguso, Attiya Harit, Nicholas N. Nissen, James Mirocha, Andrew Eugene

Hendifar, Farin F. Amersi. Prognostic factors influencing survival in small bowel

neuroendocrine tumors with liver metastasis. 2017 ASCO Annual Meeting, June 2-6. Chicago,

IL. J Clin Oncol 35, 2017 (suppl; abstr e 15688).

76. Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S.

Ritch, Fadi S. Braiteh, Mark Zalupski, Nathan Bahary, William Proctor Harris, Jie Pu, Carrie

Aldrich, Sihem Khelifa, Xionghua W. Wu, Joaquina Baranda, Ping Jiang, Andrew Eugene

Hendifar. Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs

AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017 (suppl; abstr

4008).

77. Arvind Manohar Shinde, Gillian K. Gresham, Andrew Eugene Hendifar, Quanlin Li, Brennan

Spiegel, Bj Rimel, Christine S. Walsh, Richard Tuli, Steven Piantadosi, Robert A. Figlin.

Correlating wearable activity monitor data with PROMIS detected distress and physical

functioning in advanced cancer patients. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL.

J Clin Oncol 35, 2017 (suppl; abstr e21689).

78. Sunil Hingorani, Andrea Bullock, Tara Seery, Lei Zheng, Darren Sigal, Paul Ritch, Fadi

Braiteh, Mark Zalupski, Nathan Bahary, William Harris Jie Pu, Carrie Aldrich, Sihem Khelifa,

Wilson Wu, Joaquina Baranda, Ping Jiang, Andrew Hendifar. PEGPH20 improves PFS in

patients with metastatic pancreatic ductal adenocarcinoma: a randomized phase 2 study in

combination with nab-paclitaxel/gemcitabine. 2017 ESMO World Congress on

Gastrointestinal Cancer, June 28-July 1. Barcelona, Spain. Ann Oncol. 2017. (supp, abstract O

003).

79. Andrew Hendifar, Andrea Bullock, Tara Seery, Lei Zheng, Darren Sigal, Paul Ritch, Fadi

Braiteh, Mark Zalupski, Nathan Bahary, William Harris Jie Pu, Fangru Lian, Junming Zhu,

Wilson Wu, Joaquina Baranda, Ping Jiang, Sunil Hingorani. Tumor hyaluronan may predict

benefit from PEGPH20 when added to nab paclitaxel/gemcitabine in patients with previously

untreated metastatic pancreatic ductal adenocarcinoma (mPDA). 2017 ESMO World Congress

on Gastrointestinal Cancer, June 28-July 1. Barcelona, Spain. Ann Oncol 28, 2017. (sup_3,

abstract O-028).


80. E Van Cutsem, A Hendifar, M Reni, L Zheng, M Ducreaux, W Harris, P Corrie, T Seery, D

Chondros, A Bullock. Global phase 3, randomized, double-blind, placebo-controlled study

evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) + nab-paclitaxel

& gemcitabine in patients with previously untreated, hyaluronan-high, stage IV pancreatic

ductal adenocarcinoma. 2017 ESMO World Congress on Gastrointestinal Cancer, June

28-July 1. Barcelona, Spain. Ann Oncol 28, 2017. (sup_3, P-043).

81. I Lapite, M Guan, A Hendifar. Patient Preferences for Quality of Life Domains in Pancreatic

Cancer. 3rd Annual Research Internship Poster Day. Cedars-Sinai Medical Center. Los

Angeles, CA. August 4, 2017.

82. M Guan, I Lapite, BK Larson, D Pan, J Khanuja, R Patel, J Zhou, A Osipov, M Guindi, T

Muller, Q Li, P Jiang, R Tuli, A Hendifar. Association Between Hyaluronic Acid Expression

and Clinical/Pathological Variables in Pancreatic Ductal Adenocarcinoma. 3rd Annual

Research Internship Poster Day. Cedars-Sinai Medical Center. Los Angeles, CA. August 4,

2017.

83. J Strosberg, EM Wolin, B Chasen, MH Kulke, D Bushnell, M Caplin, RP Baum, P Kunz, T

Hobday, A Hendifar, K Öberg, M Lopera Sierra, P Ruszniewski, E Krenning. Improved time

to quality of life deterioration in patients with progressive midgut neuroendocrine tumors

treated with 177Lu-Dotatate: the NETTER-1 phase III trial. 2017 ESMO Congress, September

8-12. Madrid, Spain. Ann Oncol 28 (Supplement 5), September 2017. (PD #438)

84. A Hendifar, A Bullock, . Seery, L Zheng, D Sigal, PS Ritch, FS Braiteh, M Zalupski, N

Bahary, W Harris, J Pu, F Lian, J Zhu, W Wu, D Chondros, P Jiang, SR Hingorani. Tumor

hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of

PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated,

metastaticpancreatic ductal adenocarcinoma (mPDA). 2017 ESMO Congress, September 8-12.

Madrid, Spain. Ann Oncol 28 (Supplement 5), September 2017. (P #743)

85. A Bullock, P Vervaet, W Wu, D Chondros, SR Hingorani, A Hendifar. Musculoskeletal

Events (MSEs) with PEGPH20 treatment and management in patients with previously

untreated metastatic pancreatic ductal adenocarcinoma (mPDA). 2017 ESMO Congress,

September 8-12. Madrid, Spain. Ann Oncol 28 (Supplement 5), September 2017. (P #749)

86. SR Hingorani, A Bullock, T Seery, L Zheng, D Sigal, PS Ritch, FS Braiteh, M Zalupski, N

Bahary, W Harris, J Pu, C Aldrich, S Khelifa, W Wu, D Chondros, P Jiang, A Hendifar.

Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in

patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA). 2017

ESMO Congress, September 8-12. Madrid, Spain. Ann Oncol 28 (Supplement 5), September

2017. (P #763)


87. E Van Cutsem, A Hendifar, M Reni, L Zheng, M Ducreaux, W Harris, P Corrie, T Seery, D

Chondros, A Bullock. Global phase 3, randomized, double-blind, placebo-controlled study

evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus

nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high,

stage IV pancreatic ductal adenocarcinoma (PDA). 2017 ESMO Congress, September 8-12.

Madrid, Spain. Ann Oncol 28 (Supplement 5), September 2017. (TiP 774)

88. D-Y Oh, Y-J Bang, E Van Cutsem, A Hendifar, M Reni, L Zheng, M Ducreux, W Harris, P

Corrie, T Seery, D Chondros, A Bullock, C-P Li. Phase 3, randomized, double-blind,

placebo-controlled study of PEGylated recombinant human hyaluronidase PH20 (PEGPH20)

+ nab-paclitaxel/gemcitabine in patients with previously untreated, hyaluronan-high, stage IV

pancreatic ductal adenocarcinoma (PDA). ESMO Asia 2017 Congress, November 17-19.

Singapore. Ann Oncol 28 (Supplement 10, abstract #1663), November 2017. (TiP 260)

89. D-Y Oh, Y-J Bang, E Van Cutsem, A Hendifar, M Reni, L Zheng, M Ducreux, W Harris, P

Corrie, T Seery, D Chondros, A Bullock, C-P Li. Phase 3, randomized, double-blind,

placebo-controlled study of PEGylated recombinant human hyaluronidase PH20 (PEGPH20)

+ nab-paclitaxel/gemcitabine in patients with previously untreated, hyaluronan-high, stage IV

pancreatic ductal adenocarcinoma (PDA). 25th International Symposium on Advances in the

Treatment of Digestive Tumors, December 14, 2017. Seville, Spain.

90. John David, Sungjin Kim, Erik Anderson, Arman Torossian, Simon Lo, Nicholas N Nissen,

Andrew Eugene Hendifar, Richard Tuli. Treatment at high-volume facilities and academic

centers in relation to overall survival in patients with locally advanced pancreatic cancer: A

National Cancer Database analysis. 2018 Gastrointestinal Cancers Symposium, January 18-20.

San Francisco, CA. J Clin Oncol 36, 2018 (suppl 4S; abstr 392). (PS)

91. Eric Anderson, John David, Simon Lo, Nicholas N Nissen, Andrew Eugene Hendifar,

Richard Tuli. Curative intent surgery and associated overall survival variation between elderly

and younger patients in the National Cancer Database. 2018 Gastrointestinal Cancers


(PS)

92. John David, Sungjin Kim, Eric Anderson, Arman Torossian, Simon Lo, Nicholas N Nissen,

Andrew Eugene Hendifar, Richard Tuli. Effect of multiagent chemotherapy and

chemoradiotherapy on rates of resection and survival in patients with locally advanced

pancreatic cancer: a National Cancer Database Analysis. 2018 Gastrointestinal Cancers


(PS)

93. John David, Yong Yue, Kevin Blas, Benedick Fraass, Andrew Eugene Hendifar, Peyman

Kabolizadeh, Richard Tuli. 18F-FDG PET-defined therapy response to predict acute

hematologic toxicity for anal cancer patients treated with chemoradiation. 2018




94. Aatur D. Singhi, Joel R Greenbowe, Jon Chung, Andrew Eugene Hendifar, Nathan Bahary,

Alexa Betzig Schrock, Vincent A Miller, Philip J Stephens, Jeffrey S Ross, Siraj Mahamed Ali,

Ben George. Comprehensive genomic profiling to identify recurrent kinase fusions in

pancreatic ductal adenocarcinoma. 2018 Gastrointestinal Cancers Symposium, January 18-20.


95. Michelle Guan, R Joseph Bender, Michael J Pishvaian, David Charles Halverson, Richard Tuli,

Samuel Jacob Klempner, Zev A Wainberg, Aatur D Singhi, Emanuel Petricoin, Andrew

Eugene Hendifar. Molecular and clinical characterization of BRAF mutations in pancreatic

ductal adenocarcinomas (PDACs). 2018 Gastrointestinal Cancers Symposium, January 18-20.


96. Ben George, Joel R Greenbowe, Andrew Eugene Hendifar, Talia Golan, Milind M Javle,

Anirban Maitra, Nathan Bahary, Alexa Betzig Schrock, Philip J Stephens, Vincent A Miller,

Jeffrey S Ross, Evgeny Yakirevich, Paul S Ritch, James P Thomas, Siraj Mahamed Ali, Aatur

D Singhi. Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal

adenocarcinoma (PDAC). 2018 Gastrointestinal Cancers Symposium, January 18-20. San

Francisco, CA. J Clin Oncol 36, 2018 (suppl 4S; abstr 271). (PS)

97. Gagandeep Brar, Edik Blais, R Joseph Bender, Jonathan Brody, Davendra Sohal, Subha

Madhavan, Vincent J Picozzi, Andrew Eugene Hendifar, Vincent M Chung, David

Halverson, Sameh Mikhail, Lynn McCormick Matrisian, Lola Rahib, Emanuel Petricoin,

Michael J Pishvaian. Multiomic molecular comparison of primary versus metastatic pancreatic

tumors. 2018 Gastrointestinal Cancers Symposium, January 18-20. San Francisco, CA. J Clin

Oncol 36, 2018 (suppl 4S; abstr 213). (PS)

98. Richard Tuli, Nicholas N. Nissen, Simon Lo, Miranda Bryant, Arsen Osipov, Andre Rogatko,

Mourad Tighiouart, Zhenqiu Liu, Nan Deng, Andrew Eugene Hendifar, Stephen Lawrence

Shiao. DNA repair deficiency, genomic instability and immune profiling in a phase 1 study of

locally advanced pancreatic cancer patients treated with veliparib, gemcitabine and

radiotherapy. 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36, 2018

(suppl; abstr 4128). (PS)

99. Jonathan R. Strosberg, Edward M. Wolin, Beth A. Chasen, Matthew H. Kulke, David L

Bushnell, Martyn E. Caplin, Richard P. Baum, Timothy J. Hobday, Andrew Eugene

Hendifar, Laura Ravasi, Kjell E. Oberg, Philippe B. Ruszniewski, Eric Krenning. Clinical

outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate

vs. high dose octreotide in progressive midgut neuroendocrine tumors. 2018 ASCO Annual

Meeting, June 1-6. Chicago, IL. J Clin Oncol 36, 2018 (suppl; abstr 4102). (PS)


100. Jonathan R. Strosberg, Edward M. Wolin, Beth A. Chasen, Matthew H. Kulke, David L

Bushnell, Martyn E. Caplin, Richard P. Baum, Timothy J. Hobday, Andrew Eugene

Hendifar, Maribel Lopera Sierra, Kjell E. Oberg, Philippe B. Ruszniewski, Eric Krenning.

First update on overall survival, progression-free survival, and health-related

time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose

octreotide in progressive midgut neuroendocrine tumors. 2018 ASCO Annual Meeting, June

1-6. Chicago, IL. J Clin Oncol 36, 2018 (suppl; abstr 4099). (PS)

101. Pamela L. Kunz, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre,

Carlos J. Suarez, James C. Yao, Matthew H. Kulke, Andrew Eugene Hendifar, James

Christopher Shanks, Manisha H. Shah, Mark Zalupski, Edmond L. Schmulbach, Diane

Lauren Reidy, Jonathan R. Strosberg, Peter J. O'Dwyer, Al Bowen Benson. A randomized

study of temozolomide or temozolomide and capecitabine in patients with advanced

pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group

(E2211). 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36, 2018

(suppl; abstr 4004). (OAS)

102. Subha Madhavan, Edik Matthew Blais, R Joseph Bender, Vincent M. Chung, Andrew

Eugene Hendifar, Sameh Mikhail, Maeve Aine Lowery, Davendra Sohal, Paula Raffin

Pohlmann, Kathleen N. Moore, Kai He, Bradley J. Monk, Robert L. Coleman, Thomas J.

Herzog, Emanuel Petricoin, David Charles Halverson, Michael J. Pishvaian. A

cloud-based virtual tumor board to facilitate treatment recommendations for patients with

advanced cancers. 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36,

2018 (suppl; abstr 6508). (OAS)

103. Emanuel Petricoin, R Joseph Bender, David Charles Halverson, Lola Rahib, Andrew

Eugene Hendifar, Sameh Mikhail, Vincent M. Chung, Vincent J. Picozzi, Davendra

Sohal, Lynn McCormick Matrisian, Jonathan Robert Brody, Subha Madhavan, Michael J.

Pishvaian. Precision medicine for pancreatic cancer patients:preliminary results from the

know your tumor program. 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin

Oncol 36, 2018 (suppl; abstr 4126). (PS)

104. Varun Yadav Roy, Andrew Eugene Hendifar. Portal hypertension and ascites in

pancreatic cancer. 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36,

2018 (suppl; abstr e16242).

105. Jun Gong, Michelle Guan, Cook-Wiens Galen, Brent K Larson, Jenny Zhou, Rishi Patel,

Isaac Lapite, Richard Tuli, Ronald B. Natale, Andrew Eugene Hendifar. Tumor

hyaluronan (HA) as a novel biomarker in non-small cell lung cancer (NSCLC). 2018

ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36, 2018 (suppl; abstr

e24280).

106. Andrew E. Hendifar, Michelle Guan, Veronica Placencio, Theresa Zimmers. Focus on

pancreatic cancer cachexia: clinical trials in progress. 4th Cancer Cachexia Conference,

September 14-16. Philadelphia, PA.


107. Ingrid He, Michael Luu, Veronica Placencio, Varun Roy, John David, Michelle Guan,

Richard Tuli, Andrew Hendifar. Palliative radiotherapy for skeletal-related events in

neuroendocrine tumors. NANETS Annual Multidisciplinary NET Disease Symposium,

October 4-6, 2018. Seattle, WA. (P)

108. TA Rich, K Clifton, A Grothey, A Hendifar, DH Henry, Y Kagawa, Y Nakamura, W

Okamoto, BR Tan, G Sherrill, T Yoshino, VM Raymond, Y Shiotsu, RB Lanman, V

Morris. RET rearrangements may arise following anti-EGFR therapy in advanced

colorectal cancer. 43rd ESMO Congress (ESMO 2018), October 19-23. Munich, Germany.

Ann Oncol 29, 2018 (suppl 8; abstr 482P). (PP)

109. T Macarulla Mercade, A Hendifar, C-P Li, M Reni, H Riess, MA Tempero, A Dueck, MF

Botteman, C Deshpande, E Lucas, DY Oh. Health-related quality of life (HRQoL) in

patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant

chemotherapy (A/NAC): A systematic literature review (SLR). 43rd ESMO Congress

(ESMO 2018), October 19-23. Munich, Germany. Ann Oncol 29, 2018 (suppl 8; abstr

741P) (PP)

110. E Van Cutsem, PG Corrie, MP Ducreux, D Sigal, V Sahai, D-Y Oh, A Bullock, Y-J Bang,

AD Baron, A Hendifar, C-P Li, P Philip, M Reni, M. Zalupski, L Zheng, C Berman, D.

Chondros, MA Tempero. HALO 109-301: Phase 3, randomized, double-blind,

placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) +

nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan

(HA)-high Stage IV pancreatic ductal adenocarcinoma (PDA). 43rd ESMO Congress

(ESMO 2018), October 19-23. Munich, Germany. Ann Oncol 29, 2018 (suppl 8; abstr

789TiP) (PP)

111. J Strosberg, A Hendifar, JC Yao, M Kulke, T O’Dorisio, M Caplin, RP Baum, P Kunz, T

Hobday, E Wolin, ES Mittra, K Oberg, P Ruszniewski, B Polack, B He, D Barton, P

Santaro, E Krenning. Impact of liver tumor burden on therapeutic effect of 177Lu-Dotatate

treatment in NETTER-1 study. 43rd ESMO Congress (ESMO 2018), October 19-23.

Munich, Germany. Ann Oncol 29, 2018 (suppl 8; abstr 1316P) (PP)

112. V Roy, G Cook-Wiens, M Guan, V Placencio, A Torosian, J Gong, I He, A Osipov, R Tuli,

A Hendifar. Portal hypertension in pancreatic cancer is associated with radiation therapy.

49th American Pancreatic Association (APA) Annual Meeting, October 31-November 3,

2018. Miami, Beach. FL. (PP)

Andrew E. Hendifar, MD, MPH PROFESSIONAL CONTACT …

Documents

Transcript of Andrew E. Hendifar, MD, MPH PROFESSIONAL CONTACT …